<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">109145</article-id>
<article-id pub-id-type="doi">10.7554/eLife.109145</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.109145.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.3</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories><title-group>
<article-title>Synergistic <italic>MAPT</italic> mutations as a platform to uncover modifiers of tau pathogenesis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7105-0628</contrib-id>
<name>
<surname>Bryan</surname>
<given-names>Miles R</given-names>
<suffix>III</suffix></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almeida</surname>
<given-names>Michael F</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pellegrino</surname>
<given-names>Kyle</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Opland</surname>
<given-names>Carli K</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paulakonis</surname>
<given-names>J Ethan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGillion-Moore</surname>
<given-names>Jake</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trzeciakiewicz</surname>
<given-names>Hanna</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>King</surname>
<given-names>Diamond</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Xu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tseng</surname>
<given-names>Jui-Heng</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7382-2783</contrib-id>
<name>
<surname>Schisler</surname>
<given-names>Jonathan C</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Nicholas G</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bahr</surname>
<given-names>Ben A</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cohen</surname>
<given-names>Todd J</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<email>toddcohen@neurology.unc.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Neurology, University of North Carolina-Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0566a8c54</institution-id><institution>Duke-University of North Carolina Alzheimer’s Disease Research Center (ADRC)</institution></institution-wrap>, <city>Durham</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>McAllister Heart Institute and the Department of Pharmacology, University of North Carolina - Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Pharmacology, University of North Carolina-Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03efmqc40</institution-id><institution>School of Life Sciences, Arizona State University-Tempe</institution></institution-wrap>, <city>Tempe</city>, <country country="US">United States</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05pckj715</institution-id><institution>Biotechnology Research and Training Center, University of North Carolina-Pembroke</institution></institution-wrap>, <city>Pembroke</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Ye</surname>
<given-names>Keqiang</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id>
<institution>Chinese Academy of Sciences</institution>
</institution-wrap>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ron</surname>
<given-names>David</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3014-5636</contrib-id>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id>
<institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country country="GB">United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-12-22">
<day>22</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP109145</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-10-03">
<day>03</day>
<month>10</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-10-08">
<day>08</day>
<month>10</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.02.07.636933"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Bryan et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Bryan et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-109145-v1.pdf"/>
<abstract><p>The natively unfolded tau (MAPT) protein is extremely soluble, which poses challenges when modeling neurofibrillary tangle (NFT) pathology in Alzheimer’s disease (AD). To overcome this hurdle, we combined P301L and S320F mutations (PL-SF) to generate a rapid and reliable tau pathology platform to expedite the discovery of factors that modify tau aggregation. Using this model, we evaluated heat-shock proteins (Hsp), which have been linked to tau pathology, but whose role in AD remains enigmatic and controversial. In primary neurons, expression of Hsp70, but not Hsc70 or Hsp90, exacerbated tau aggregation. Conversely, lowering Hsp70 or employing a chaperone-deficient tau mutant (PL-SF-4Δ) reduced tau phosphorylation and abrogated tau aggregation, highlighting Hsp70 as a key driver of tau aggregation. Hsp70 foci clustered within and surrounding neuritic plaques and NFTs in post-mortem AD brain. Functionally, mature aggregate-bearing neurons showed deficits in neuronal firing and network communication, which were restored by chaperone-binding deficient tau variants that abrogated tau pathology. This study provides a powerful cell-intrinsic model for accelerated tau aggregation, which can be harnessed to identify potent regulators of tau aggregation as promising therapeutic targets.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>aggregation</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>FTDP-17</kwd>
<kwd>MAPT</kwd>
<kwd>posttranslational modification (PTM)</kwd>
<kwd>heat-shock proteins</kwd>
<kwd>Hsp70</kwd>
<kwd>organotypic brain slices</kwd>
<kwd>neurodegeneration</kwd>
<kwd>tau</kwd>
<kwd>tauopathy</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Additional citations were included in the introduction.
First name was added for author Jake McGillion-Moore.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Aggregation of the microtubule-associated protein tau (MAPT) and the formation of insoluble tau inclusion pathology are hallmark features of Alzheimer’s disease and related neurodegenerative disorders. In contrast to AD, in which tau pathology is comprised of normal wild-type tau proteins, pathogenic disease-causing mutations in <italic>MAPT</italic> are implicated in familial frontotemporal dementia linked to chromosome 17 (FTDP-17). Over 50 different pathogenic <italic>MAPT</italic> missense, silent, and intronic mutations have been identified<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. In many instances, missense mutations generate loss and gain of function phenotypes including altered microtubule (MT) binding and enhanced tau aggregation propensity, which are implicated in prion-like tau spreading along defined spatial and temporal brain networks<sup><xref ref-type="bibr" rid="c2">2</xref>–<xref ref-type="bibr" rid="c4">4</xref></sup>.</p>
<p>While familial missense mutations at residue P301 (e.g., P301L and P301S) have been well characterized as aggregate-prone and MT-binding deficient, less is known about nearby mutations within the MT-binding repeat domain (MTBR)<sup><xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c6">6</xref></sup>. Our recent study characterized a panel of FTDP-17 tau mutations spanning this domain and found that the cellular surveillance machinery composed of HDAC6 and associated chaperones (e.g. Hsp70) shows increased binding to two specific mutations within the R3 domain (P301L and S320F), but not others, suggesting these two mutants are conformationally distinct and are more effectively recognized by the quality control machinery that targets tau for degradation<sup><xref ref-type="bibr" rid="c7">7</xref></sup>.</p>
<p>In separate studies, the P301L and S320F mutations were combined into the same full-length tau molecule (termed PL-SF), which generated a surprisingly aggregate-prone conformation leading to an accelerated AD-like tangle pathology, neuroinflammation, and memory impairments in mice and rhesus macaques<sup><xref ref-type="bibr" rid="c8">8</xref>–<xref ref-type="bibr" rid="c12">12</xref></sup>. Thus, PL-SF could potentially be leveraged as an intrinsic, cell-autonomous, and seeding-independent model of full-length tau aggregation, which would otherwise be challenging to achieve with full-length tau. In fact, many widely used tau models, including the tau biosensor cell lines, employ artificially truncated tau mutants comprising only the tau repeat domain, a fragment with questionable physiological relevance to neurons<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. In comparison, the PL-SF model offers several advantages, including serving as a rapid model of full-length and mature tau aggregation as a cornerstone for high-throughput discovery of tau modifiers<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c14">14</xref></sup>.</p>
<p>Among known tau interactors, heat shock proteins (Hsps) such as inducible Hsp70, constitutive Hsc70and related Hsp90 have high affinity for aberrant forms of tau, yet their functions as refolding and/or triaging factors remains unclear<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref>–<xref ref-type="bibr" rid="c25">25</xref></sup>. This debate has obvious therapeutic implications since Hsp inhibitors are in clinical development and have been evaluated in preclinical models of AD<sup><xref ref-type="bibr" rid="c26">26</xref>–<xref ref-type="bibr" rid="c31">31</xref></sup>. However, prior studies have yielded quite contradictory and even opposing results, since on the one hand, Hsp70 is thought to promote the MC1-positive tau conformation<sup><xref ref-type="bibr" rid="c18">18</xref></sup>, while other studies suggest Hsp70 and Hsc70 mediate tau degradation via autophagy and the ubiquitin-proteasome system (UPS)<sup><xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c33">33</xref></sup>. One possible explanation for these discrepancies is the inability to generate mature tau pathology in these studies, as observed in human AD brains. Adding additional complexity, tau interacts with dozens of chaperone adaptors and cofactors that may promote or suppress chaperone function directed towards tau<sup><xref ref-type="bibr" rid="c20">20</xref>,<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c34">34</xref>,<xref ref-type="bibr" rid="c35">35</xref></sup>. Here, we characterized a tau PL-SF model of accelerated tau pathology, which allowed us to interrogate the role of Hsp70 and other chaperones as bona fide modifiers of tau-mediated toxicity and aggregation.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Synergistic familial <italic>MAPT</italic> mutations drive tau phosphorylation and aggregation</title>
<p>We first evaluated tau aggregation in PL-SF expressing immortalized QBI-293 cells. Cells transfected with human T40 (2N4R) wild-type, P301L, S320F, or PL-SF were monitored for RIPA-soluble expression of phosphorylated tau (AT8 and AT100) and cleaved tau (TauC3), two well-established markers of tau pathogenesis. Phosphorylated tau accumulated in PL-SF expressing cells, more so than WT or either single mutant (<xref rid="fig1" ref-type="fig">Figure 1 A, B</xref>). Confirming this finding, total tau immunoblotting revealed up-shifted tau protein bands in SF and PL-SF, indicative of tau hyperphosphorylation. Surprisingly, the single PL mutant appeared hypo-phosphorylated compared to WT or SF mutations. Immunocytochemistry confirmed these findings and revealed Thioflavin S (ThioS) positive SF and PL-SF aggregates, consistent with enhanced tau aggregation (<xref rid="figs1" ref-type="fig">Supplemental Figure 1</xref>, <xref rid="fig1" ref-type="fig">Figure 1C</xref>). Similar to phosphorylated tau, cleaved tau also preferentially accumulated in SF or PL-SF expressing cells.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>Abrogating tau binding to heat shock proteins alleviates pathology in a PL-SF tau aggregation model.</title>
<p><bold>A)</bold> Representative immunoblots (RIPA fraction) of QBI-293 cells transfected with 2N4R WT, P301L, S320F, or P301L-S320F tau. <bold>B)</bold> Immunoblot quantification of total tau, p-tau (AT8 and AT100), and cleaved tau (TauC3) in RIPA fraction. N=4 per condition; <bold>C)</bold> Immunocytochemistry quantification of QBI-293 cells transduced with WT, P301L, S320F, or PL-SF tau labeled with AT8, TauC3, or ThioS. N=48 FOVs per condition. *= p-value significant by one-way ANOVA. Representative images found in <xref rid="figs1" ref-type="fig">Supplemental Figure 1</xref>. <bold>D)</bold> Representative immunoblots (RIPA fraction) of QBI-293 cells transfected with 2N4R P301L-S320F tau or P301L-S320F 4Δ (deletion of I277/278, I308/V309 residues). *AT100 was run on a separate blot with the exact same lysates to improve detection. <bold>E)</bold> Immunoblot quantification of total tau, p-tau (AT8 and AT100), and cleaved tau (TauC3) in RIPA soluble fractions. N=3 per condition. <bold>F)</bold> Immunocytochemistry quantification of QBI-293 cells transduced with 2N4R PL-SF or PL-SF 4Δ tau labeled with AT8, TauC3, or ThioS. N=16 FOVs per condition. *= p-value significant by unpaired Student’s t-test. Representative images found in <xref rid="figs3" ref-type="fig">Supplemental Figure 3</xref>. <bold>G)</bold> Co-immunoprecipitation of QBI-293 cells transfected with WT, P301L, PL-SF, or PL-SF 4Δ tau. Tau5 antibody was used to IP tau and immunoblots were probed with total tau (rabbit polyclonal) and Hsp70, Hsc70, and Hsp90 antibodies. <bold>H)</bold> Representative immunoblots of QBI-293 cells transfected with 2N4R tau variants and probed with acetyl-tubulin and total alpha-tubulin antibodies. Note: Acetyl tubulin and alpha tubulin blots were run separately with the same lysates to improve detection. <bold>I)</bold> Quantification of acetyl-tubulin across all 2N4R tau variants. -- line signifies separate sets of transfections in panel I and J. N=4 per condition; *= p-value significant by one-way ANOVA. Control= empty plasmid vector (pcDNA3.1). <bold>J)</bold> Quantification of in vitro Thioflavin T aggregation assay using purified protein from PLSF and PLSF 4Δ. N=4 replicates per condition. *= significant by unpaired student t-test at 12hr timepoint. Coomassie (right) shows equal protein loading into reactions.</p></caption>
<graphic xlink:href="636933v3_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Multiple familial FTD-associated mutations occur at residue P301 (P301L, P301S, P301T) and S320 (S320F, S320Y). We evaluated a panel of other combination mutants by immunoblotting and immunocytochemistry and found that all double mutants formed phosphorylated, cleaved, and insoluble tau species compared to individual single tau mutants (<xref rid="figs2" ref-type="fig">Supplemental Figure 2</xref>). The most consistently insoluble tau species was PL-SF, which we selected for follow-up analysis.</p>
<p>A prior study found that deletion of four key residues in tau (I277/I278 and I308/V309) can abrogate Hsp70 binding<sup><xref ref-type="bibr" rid="c36">36</xref></sup>. Since the role of Hsp70 in tau pathology is unclear, we generated a PL-SF mutant in which these four residues were depleted, termed PL-SF 4Δ. In transfected QBI-293 cells, PL-SF 4Δ was nearly completely dephosphorylated and accumulated negligible amounts of cleaved tau. PL-SF 4Δ was also downshifted compared to PL-SF (<xref rid="fig1" ref-type="fig">Figure 1D, E</xref>) and showed significantly less phosphorylated (AT8), cleaved (TauC3), and aggregated (ThioS) tau (<xref rid="figs3" ref-type="fig">Supplemental Figure 3</xref>, <xref rid="fig1" ref-type="fig">Figure 1F</xref>). By co-immunoprecipitation assays, we confirmed that PL-SF 4Δ abrogated the majority of Hsc70 and Hsp70 binding to tau. We did not observe detectable and specific binding to endogenous Hsp90 in our model (<xref rid="fig1" ref-type="fig">Figure 1G</xref>).</p>
<p>We also assessed the impact of tau mutants on acetylated-tubulin (ac-tubulin), a readout for microtubule (MT) stability and dynamics. Wild-type tau increased ac-tubulin, as expected, while P301L or S320F were less effective (∼30-40%). Consistent with a near-complete loss of MT regulatory function, PL-SF reduced ac-tubulin levels down to the levels of non-transfected cells. Surprisingly, PL-SF 4Δ partly restored the tubulin interactions (<xref rid="fig1" ref-type="fig">Figure 1H, I</xref>).</p>
<p>To confirm that PL-SF has increased intrinsic propensity to self-aggregate, as opposed to being influenced by other cellular factors, we performed in vitro Thioflavin T (ThioT) assays using recombinant purified tau proteins to assess aggregation kinetics in the presence of heparin as an inducing agent. Indeed, PL-SF tau rapidly aggregated within 1 hr post-induction, at which point the formation of recombinant tau fibrils plateaued, while PL-SF 4Δ was completely resistant to aggregation, even though similar tau concentrations were present (<xref rid="fig1" ref-type="fig">Figure 1J</xref>).</p>
</sec>
<sec id="s2b">
<title>Impaired chaperone binding alleviates tau pathology in neurons</title>
<p>To validate our findings in neurons, we developed mutant tau lentiviral constructs suitable for high-efficiency transduction into mouse primary cortical neurons. Transduced primary neurons were evaluated with a panel of tau mutants, including PL-SF. Immunoblotting of neuronal lysates showed that PL-SF tau was again up-shifted and accumulated more phosphorylated tau (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>). Unlike immortalized cell lines, neurons did not show appreciable levels of cleaved tau (TauC3). Only PL-SF accumulated in the insoluble fraction (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). PL-SF 4Δ showed a marked reduction in tau phosphorylation and aggregation, suggesting a similar phenotype in neurons as well. In fact, deletion of just two of the Hsp-binding residues (ΔI277/I278 or ΔI308/V309) abrogated tau phosphorylation and aggregation, with residues I308/V309 showing the most dominant effect (<xref rid="fig2" ref-type="fig">Figure 2A-C</xref>). Introduction of β-sheet disrupting proline mutations has been shown to abrogate tau aggregation<sup><xref ref-type="bibr" rid="c37">37</xref>–<xref ref-type="bibr" rid="c41">41</xref></sup>. Indeed, by mutating residues I277 and I308 to prolines (PL-SF I277P/I308P), we were able to suppress tau aggregation to similar levels as seen in PL-SF 4Δ (<xref rid="figs4" ref-type="fig">Supplemental Figure 4</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Development and characterization of a PL-SF tau aggregation model in primary cortical neurons.</title>
<p><bold>A)</bold> Representative RIPA-soluble immunoblots of DIV10 primary cortical neurons transduced with lentiviruses expressing 2N4R WT, P301L, S320F, P301L-S320F, or PL-SF 2Δs (R2 and R3) and 4Δ tau variants. <bold>B)</bold> Quantification of AT8, AT100, AT180, and total tau immunoblots in primary cortical neurons (RIPA fraction). N=3 per condition; *= p-value significant by one-way ANOVA. <bold>C)</bold> Representative SDS-soluble immunoblots of DIV10 primary cortical neurons transduced with lentiviruses expressing 2N4R WT, P301L, S320F, P301L-S320F, or PL-SF 2Δ and 4Δ tau variants. N=2 for control, WT, and P301L; N=3 for other variants. <bold>D)</bold> Representative immunocytochemistry images of 2N4R tau variants labeled with AT8 (p-tau), MC1 (conformational tau), ThioS (aggregated tau) in GFP. Scale bar= 125 µm. <bold>E)</bold> Quantification of the number of AT8, MC1, and ThioS inclusions in PL-SF and PL-SF 2Δ (R2 and R3) and 4Δ variants. N=12-24 FOVs per condition. *= significant by one-way ANOVA. <bold>F, G)</bold> Representative immunocytochemistry images of PL-SF tau displaying colocalization between F) AT8 (p-tau) or G) MC1 (conformational tau) with ThioS (aggregated tau). Scale bar= 50um. <bold>H)</bold> Representative immunocytochemistry of PL-SF GFP colocalized with T49 tau (mouse-specific). Scale bar= 125 µm. Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>By performing microscopy on transduced neurons, we found that PL-SF accumulated AT8, MC1, and ThioS-positive tau inclusions (<xref rid="fig2" ref-type="fig">Figure 2D, E</xref>). Both MC1 (pre-tangle confirmational tau) and AT8 immunoreactive tau were amorphous and globular and accumulated as large varicosities, or swellings, within neurites. The large globular tau aggregates colocalized with ThioS, supporting tangle-like pathology (<xref rid="fig2" ref-type="fig">Figure 2F, G</xref>). By transducing neuronal cultures with GFP-tagged PL-SF and labeling neurons with a mouse-specific tau antibody (monoclonal T49), we observed recruitment of endogenous mouse tau to PL-SF inclusions, implying that no species barrier exists between human PL-SF aggregates and mouse tau (<xref rid="fig2" ref-type="fig">Figure 2H</xref>). PL-SF behaved similarly in tau knockout neurons, and therefore, endogenous tau is not required for the accumulation of PL-SF pathology in neurons (<xref rid="figs5" ref-type="fig">Supplemental Figure 5</xref>).</p>
</sec>
<sec id="s2c">
<title>Hsp70 promotes tau hyperphosphorylation and aggregation</title>
<p>To determine whether Hsp70 is a more potent regulator of tau pathology compared to other tau-associated heat shock proteins, PL-SF expressing neurons were co-transduced with either HSP70, HSC70, or HSP90. Only Hsp70, but not Hsc70 or Hsp90, exacerbated tau phosphorylation (AT8), which was supported by an appreciable upshift in tau’s molecular weight (<xref rid="fig3" ref-type="fig">Figure 3A, B</xref>) and a trend towards increased levels of total insoluble tau (<xref rid="fig3" ref-type="fig">Figure 3C, D</xref>). Hsp70 significantly increased AT8, MC1, and ThioS immunoreactivity (<xref rid="fig3" ref-type="fig">Figure 3E, F</xref>). The effect of Hsp70 appears remarkably specific to the aggregate-prone PL-SF tau, since the P301L single mutant was unaffected (<xref rid="figs6" ref-type="fig">Supplemental Figure 6</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Hsp70 exacerbates tau hyperphosphorylation and aggregation.</title>
<p><bold>A)</bold> Representative immunoblots of 2N4R PL-SF tau co-transduced with HSP70, HSC70, and HSP90 in DIV10 primary cortical neurons (RIPA fraction). <bold>B)</bold> Quantification of AT8 (p-tau), total tau (rabbit polyclonal), or Hsp70, Hsc70, Hsp90 (FLAG-tagged) in the RIPA fraction. N=6 per condition. *= p-value significant by one-way ANOVA. <bold>C)</bold> Representative immunoblots of 2N4R PL-SF tau co-transduced with HSP70, HSC70, and HSP90 in DIV10 primary cortical neurons (SDS fraction). <bold>D)</bold> Quantification of AT8 (p-tau), total tau (rabbit polyclonal) in the SDS fraction. N=6 per condition. ns= p-value is not significant by one-way ANOVA. <bold>E)</bold> Representative immunocytochemistry images of primary cortical neurons co-transduced 2N4R PL-SF tau and HSP70, HSC70, or HSP90 labeled with AT8, MC1, Tau12 (RFP) or ThioS (GFP). Scale bar= 125 µm. <bold>F)</bold> Quantification of MC1, AT8, and ThioS positive inclusions in primary cortical neurons co-transduced 2N4R PL-SF tau and either HSP70, HSC70, or HSP90. n=12 FOVs per condition. *= p-value significant by one-way ANOVA. Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Next, we depleted HSP70 in PL-SF transduced neurons. We achieved ∼ 50% Hsp70 knockdown using lentiviral shRNA transduction, which did not affect HSC70 expression. Strikingly, HSP70 knockdown led to ∼70% decrease in phosphorylated tau (<xref rid="fig4" ref-type="fig">Figure 4 A, B</xref>) and ∼50% decrease in total insoluble tau (<xref rid="fig4" ref-type="fig">Figure 4C, D</xref>). We note that a ∼50% decrease in soluble tau was also observed, suggesting that Hsp70 depletion enhances the turnover of steady-state tau levels (<xref rid="fig4" ref-type="fig">Figure 4A, B</xref>). The impact of Hsp70 on tau also appears to be quite specific since knockdown of HSP90 did not alter total or phosphorylated tau (<xref ref-type="fig" rid="figs7">Supplementary Figure 7</xref>). Overall, our findings highlight Hsp70 as a primary regulator of aggregate-prone tau species in this accelerated PL-SF tau model.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>Reducing Hsp70 can suppress tau hyper-phosphorylation and aggregation.</title>
<p><bold>A)</bold> Representative immunoblots of 2N4R PL-SF tau co-transduced with a shRNA against HSP70 in DIV10 primary cortical neurons (RIPA fraction). <bold>B)</bold> Quantification of AT8 (p-tau), total tau (rabbit polyclonal) and endogenous Hsp70 and Hsc70 in the RIPA fraction. N=3. <bold>C)</bold> Representative immunoblots of 2N4R PL-SF tau co-transduced a shRNA against HSP70 in DIV10 primary cortical neurons (SDS fraction). <bold>D)</bold> Quantification of AT8 (p-tau), total tau (rabbit polyclonal) in the SDS fraction. N=3. *= p-value significant by unpaired Student’s t-test. Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>Cell-autonomous aggregated tau alters neuronal activity and network synchrony</title>
<p>Given the extensive tau pathology observed in PL-SF transduced neurons, we evaluated any deficits in neuronal activity and connectivity. Electrically active neurons were transduced at DIV18 following an initial multi-electrode array (MEA) recording. Daily recordings were taken for 53 days, and in parallel, neurons were immunolabeled at DIV29 and DIV62 to assess the extent of tau pathology.</p>
<p>We evaluated the mean firing rate (a measure of overall activity), the number of network bursts (a measure of neuronal connectivity), and the area under the normalized crossed-correlation (a readout for neuronal synchrony). After 15-20 days post-lentiviral transduction, PL-SF neurons showed a decline in all three metrics, suggesting a loss in neuronal activity and reduced synchronous firing across neuronal networks. The deficits worsened over time, but some neurons continued to fire even past DIV50 (<xref rid="fig5" ref-type="fig">Figure 5A-C</xref>). Raster plots at DIV54 highlight reduced network firing across electrodes and elongated network firing time (<xref rid="fig5" ref-type="fig">Figure 5D-F</xref>). PL-SF 4Δ did not exhibit any deficits in any of the activity metrics and showed similar firing patterns as compared to wild-type control neurons (<xref rid="fig5" ref-type="fig">Figure 5A-C</xref>).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption><title>Mature tau aggregates cause functional deficits in neurons that are reversed by abrogating tau-Hsp binding.</title>
<p><bold>A-C)</bold> Quantification of neuronal activity comparing PL-SF to PL-SF 4Δ across 53 days of multi-electrode array recording starting at DIV18 following initial pre-recording. A) Mean firing rate-activity B) Number of network bursts-connectivity C) Area under normalized cross-correlation-synchrony. N=4 replicate wells per condition. *= p-value significant by one-way ANOVA. <bold>D-F)</bold> Representative raster and network burst plots at DIV54 (day 36 of recording) comparing empty control (pUltra) to PL-SF and PL-SF 4Δ. D) Number of network bursts across electrodes over time (pink lines) E) number of spikes across electrodes over time F) Average number of spikes per network burst over time. <bold>G)</bold> Representative immunoblot of isolated post synaptic density (PSD) in DIV18 primary cortical neurons transduced with lentiviruses expressing P301L, PL-SF, or PL-SF 4Δ. Immunoblot was probed with PSD95, AT8 (p-tau), and rabbit polyclonal tau (total tau). <bold>H)</bold> Representative 20X immunocytochemistry images of primary cortical neurons comparing empty vector control (pUltra) to PL-SF and PL-SF 4Δ tau variants at DIV29 and DIV62. Neurons were labeled with ThioS (aggregated tau), MC1 (conformational tau), AT8 (p-tau), and Tau12 (total tau) in GFP. Tau12 was co-labeled with GFAP (RFP) to label astrocytes. Scale bar= 125 µm. <bold>I)</bold> Representative immunocytochemistry images of primary cortical neurons comparing PL-SF and PL-SF 4Δ at DIV29. Neurons were labeled with endogenous Hsp70 (GFP), MC1 or AT8 (RFP), and DAPI (BFP). Scale bar= 50 µm. Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The impact of aggregate-prone tau mutants on neuronal firing could represent a direct effect of tau at the synapse. Therefore, we assessed whether PL-SF accumulated at the post-synaptic density (PSD), a re-localization thought to coincide with synaptic dysfunction. PSD fractions were biochemically isolated from transduced neurons at DIV18 and probed by immunoblotting for phosphorylated and total tau. PL-SF accumulated in the PSD fraction, which was not observed with PL-SF 4Δ or any single tau mutants (e.g., P301L) (<xref rid="fig5" ref-type="fig">Figure 5G</xref>). We conclude that mature PL-SF tau aggregates accumulate at the PSD and drive synaptic dysfunction. By abrogating Hsp binding, PL-SF 4Δ bypasses these defects.</p>
<p>PL-SF expressing neurons were aged in culture to determine tau phenotypes over time. Indeed, aged neurons accumulated dense tau inclusions comprised of phosphorylated, MC1, and ThioS-positive tau at DIV29, which became even more intensely labeled by DIV62. All indicators of tau pathology were absent in PL-SF 4Δ expressing neurons, even at late time points (<xref rid="fig5" ref-type="fig">Figure 5H</xref>). We also note that Hsp70 began to colocalize with aggregated tau in aged neurons (<xref rid="fig5" ref-type="fig">Figure 5I</xref>), supporting aggregation-dependent recruitment of Hsp70.</p>
</sec>
<sec id="s2e">
<title>Cell-autonomous tau pathology in organotypic brain slice cultures</title>
<p>To validate our findings in brain culture systems comprised of both neurons and glia, we transduced adult rat organotypic hippocampal brain slices ex vivo with either GFP alone, wild-type tau-GFP, PL-SF-GFP, or PL-SF 4Δ-GFP at DIV1 and imaged brain slices after nine weeks in culture (<xref rid="fig6" ref-type="fig">Figure 6A, B</xref>). Similar to cultured neurons, PL-SF accumulated dense AT8 and MC1-positive inclusions and distinct neuritic puncta, or foci. Most tau pathology preferentially accumulated in the dentate gyrus (DG) and extended through the hippocampal CA1 and CA3 regions. In contrast, PL-SF 4Δ exhibited diffuse, non-aggregated neuronal labeling in the DG and showed far lower levels of pathogenic tau markers, such as MC1 and AT8 (<xref rid="fig6" ref-type="fig">Figure 6C, D</xref>). These data suggest that, in a multicellular model with complete hippocampal architecture, abrogating tau-Hsp binding can confer neuroprotection.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><title>Abrogating tau-Hsp binding suppresses tau pathology in three-dimensional organotypic hippocampal slice cultures.</title>
<p>Rat hippocampal slices were processed for immunocytochemistry after 9 weeks in culture following lentiviral infection of eGFP empty vector control, wild-type tau, PL-SF tau, and PL-SF 4Δ. <bold>A, B)</bold> Immunocytochemistry of the entire hippocampal slice following labeling of reveal sufficient expression of PL-SF and PL-SF 4Δ lentiviruses (GFP). Left-AT8 staining; Right-MC1 staining. CA1, CA3, and DG regions are labeled in white font. White boxes denote magnified images in panel C, D. Scale bar= 500 µm. <bold>C, D)</bold> Representative immunocytochemistry images of C) AT8 and D) MC1 labeled in RFP for empty vector control, wild-type tau, PL-SF tau, and PL-SF 4Δ taken from the dentate gyrus (DG) region of the hippocampal slice culture (inset white boxes from A, B). Scale bar= 100 µm.</p></caption>
<graphic xlink:href="636933v3_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2f">
<title>Hsp70 is upregulated in human AD brain and intercalates within tau aggregates</title>
<p>Finally, we evaluated Hsp70 levels and localization in AD human post-mortem brain. Biochemical fractionation of control and AD brain lysates showed elevated Hsp70 expression in both soluble (hi-salt extracted) and insoluble (urea extracted) whole cortex AD brain homogenates (<xref rid="fig7" ref-type="fig">Figure 7A,B</xref>). Hsc70 was only upregulated in the insoluble fraction of AD brains (<xref rid="fig7" ref-type="fig">Figure 7C,D</xref>). We then performed immunohistochemistry on AD hippocampus and found that the vast majority of AT8-positive tau aggregates (plaques and tangles) were labeled by Hsp70-positive foci (<xref rid="fig7" ref-type="fig">Figure 7E</xref>, <xref rid="figs8" ref-type="fig">Supplemental Figure 8</xref>). Interestingly, the Hsp70 foci formed discrete puncta that appeared to intercalate within the AT8-positive tau neuritic plaques and neurofibrillary tangles (NFTs). This data further supports a prominent role for Hsp70 in modulating tau accumulation in human AD brain.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7:</label>
<caption><title>HSP70 is upregulated in human AD brain and intercalates within tau aggregates.</title>
<p><bold>A)</bold> Hi-Salt soluble immunoblots from control (n=5) and AD (n=6) cortical lysates probed for Hsp70, Hsc70, and GAPDH. <bold>B)</bold> Quantification of hi-salt immunoblots. *= p-value significant by unpaired Student’s t-test. <bold>C)</bold> Urea soluble immunoblots from control (n=4) and AD (n=5) probed for Hsp70 and Hsc70. <bold>D)</bold> Quantification of urea immunoblots. *= p-value significant by unpaired Student’s t-test. Overexposed Hsp70 AD sample in urea was excluded from quantification. <bold>E)</bold> Representative 63X confocal single-plane z-stacks from AD human hippocampus stained with AT8 (p-tau) and Hsp70. White arrow label neuritic plaques and white arrowheads label NFTs.</p></caption>
<graphic xlink:href="636933v3_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Here, we developed and characterized a cell-autonomous model of tau aggregation based on the synergistic aggregation of tau missense mutations at residues P301 and S320. Given the rapid and robust tau aggregation observed within days (in primary neurons), the PL-SF model readily lends itself to identifying factors that modulate tau aggregation. We leveraged this model to clarify the longstanding debate on the role of Hsp70 as a tau modifier. The PL-SF model could address the stepwise development of tau pathology and provide a more reliable and sensitive system for identifying subtle regulators of tau pathogenesis.</p>
<sec id="s3a">
<title>Synergistic tau mutants as a model of mature tauopathy</title>
<p>Prior studies have suggested that combining tau mutations at P301 and S320 (e.g. PL-SF) can lead to accelerated tau aggregation<sup><xref ref-type="bibr" rid="c8">8</xref>–<xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c14">14</xref></sup>, leading to the development of new cell culture and mammalian models that better recapitulate tau pathology. For example, the S320F mutation was introduced in P301S/S305N knock-in mice, resulting in enhanced tau pathology<sup><xref ref-type="bibr" rid="c42">42</xref></sup>. Recently, AAV-mediated delivery of PL-SF tau to rhesus macaques was able to induce rapid and progressive tau pathology, demonstrating its utility as an efficient primate model for studying AD<sup><xref ref-type="bibr" rid="c43">43</xref></sup>. Here, we analyzed the biochemical and histological properties of PL-SF in cells, cortical neurons, and organotypic brain slice cultures. Strikingly, PL-SF tau inclusions appear quite similar to those detected in post-mortem AD brain (<xref rid="fig1" ref-type="fig">Figures 1</xref>, <xref rid="fig2" ref-type="fig">2</xref>, <xref rid="fig6" ref-type="fig">6</xref>, <xref rid="fig7" ref-type="fig">7</xref>). Future cryo-EM studies may be needed to better define their ultrastructural properties<sup><xref ref-type="bibr" rid="c44">44</xref>–<xref ref-type="bibr" rid="c47">47</xref></sup>. However, if PL-SF does indeed form AD-like filaments, it may be a preferred model over other single tau variants (P301S and P301L) that lack mature amyloid structure in culture and mouse models<sup><xref ref-type="bibr" rid="c48">48</xref>,<xref ref-type="bibr" rid="c49">49</xref></sup>. The PL-SF tau variant also accumulated at the post-synaptic density (PSD), leading to functional deficits in neuronal firing and connectivity (<xref rid="fig5" ref-type="fig">Figure 5 A-H</xref>), which supports its synaptic toxicity. This rapidly maturing pathology likely allows for sensitized functional defects at the synapse.</p>
<p>Exactly how these two mutations (P301L or S320F) synergize to promote tau pathology and drive tau-mediated toxicity is unclear. But we can envision several scenarios. First, P301L and P301S have been well-characterized for disrupting MT dynamics and promoting tau aggregation; however, less is known about S320F, which is linked to Pick’s disease. Recently, S320F was found to stabilize a hydrophobic pocket of tau, exposing the <sup>306</sup>VQIVYK<sup>311</sup> amyloid motif and thereby promoting aggregation<sup><xref ref-type="bibr" rid="c5">5</xref></sup>. The combination of these two mutations likely amplifies their proclivity towards β-sheet self-assembly. To further test this, we generated PL-SF I277P/I308P containing two amyloid-breaking proline mutations within the MTBR. Indeed, insertion of β-breaking mutations suppressed tau aggregation in primary neurons (<xref rid="figs4" ref-type="fig">Supplemental Figure 4</xref>), in line with previous in vitro studies<sup><xref ref-type="bibr" rid="c37">37</xref>–<xref ref-type="bibr" rid="c41">41</xref></sup>.</p>
<p>Second, by extension of its aggregation propensity, PL-SF tau may also be more highly decorated with pathological PTMs than either single tau mutant, driving conformational changes (i.e., MC1). In this study, we only evaluated well-known tau phosphorylation epitopes (AT8, AT100, AT180), but future mass spectrometry approaches could determine the temporal emergence of global tau PTMs (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>). For instance, increased PTM complexity could create a feed-forward cycle leading to further loss of tau-MT binding. One can also envision PTM-induced loss of tau binding to quality control machinery, which typically acts in a compensatory manner to prevent aberrant tau<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. One example is the surveillance factor HDAC6, which binds and maintains tau in the deacetylated state<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. Thus, PL-SF could overburden the cellular proteostasis capacity, as suggested for human AD<sup><xref ref-type="bibr" rid="c50">50</xref>–<xref ref-type="bibr" rid="c52">52</xref></sup>.</p>
<p>Third, P301L and S320F mutations are also known to dissociate tau from microtubules, which would shift and favor their equilibrium, further concentrating tau pools in the cytosol and facilitating their aggregation. PL-SF drastically reduced acetylated-tubulin levels back down to baseline (i.e., non-tau expressing cells) (<xref rid="fig1" ref-type="fig">Figure 1 H, I</xref>), suggesting PL-SF is almost completely disassociated from microtubules and therefore more readily primed for aggregation.</p>
<p>Lastly, once formed, we found that neuronal PL-SF tau can recruit endogenous mouse tau (detected by T49 antibody) into tau inclusions (<xref rid="fig2" ref-type="fig">Figure 2H</xref>), consistent with a prior study showing that human PL-SF-expressing mice (SPAM mice) recruited endogenous mouse tau<sup><xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c14">14</xref></sup>. PL-SF tau, therefore, may be more highly seeding competent, in a species-independent manner, which could be leveraged to model tau spreading since it poses several advantages over the use of exogenously added, brain-derived AD seeds (e.g., large-scale production, reliability and reproducibility, and fully intact N-terminal domains). We reiterate that further ultrastructural studies are needed to determine whether seeding-competent PL-SF resembles human AD brain-derived tau.</p>
</sec>
<sec id="s3b">
<title>The role of Hsp70 in tau pathology</title>
<p>We added clarity to the long-standing question of whether Hsp70 modulates tau aggregation, as the prior literature is inconsistent and often highlights contradictory models for tau triage via coordinated Hsp binding. Some studies have found that activation or overexpression of Hsp70 can suppress tau aggregation in vitro, which would intuitively suggest a classical Hsp70 chaperone activity as a suppressor of tau aggregation<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c33">33</xref>,<xref ref-type="bibr" rid="c53">53</xref></sup>. Adding additional complexity, while Hsp70 can disassemble tau filaments isolated from human AD brain, this chaperone activity can release seeding-competent tau species, suggesting any protection afforded by Hsp70 may depend on the nature of the chaperone-liberated tau species<sup><xref ref-type="bibr" rid="c54">54</xref></sup>. In contrast, other studies have shown that Hsp70 depletion or small molecule inhibition (YM-01, JG-23/48) may drive tau clearance<sup><xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c23">23</xref>,<xref ref-type="bibr" rid="c28">28</xref>,<xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c55">55</xref>–<xref ref-type="bibr" rid="c57">57</xref></sup>. We sought to reconcile these differences in the context of our PL-SF cellular model of tau aggregation.</p>
<p>We initially found that Hsp70 was tightly associated with PL-SF tau aggregates in vitro and in cell culture, a finding consistent with a previous study<sup><xref ref-type="bibr" rid="c58">58</xref></sup> (<xref rid="fig5" ref-type="fig">Figure 5I</xref>). HSP70 overexpression was associated with PL-SF phosphorylation and aggregation, while HSP70 depletion reduced total tau levels, including hyperphosphorylated and aggregated tau species (<xref rid="fig3" ref-type="fig">Figure 3A-D</xref>, <xref rid="fig4" ref-type="fig">Figure 4A-D</xref>). Furthermore, abrogating Hsp70 binding using an Hsp70-binding deficient mutant (PL-SF-4Δ) was also sufficient to suppress tau aggregation (<xref rid="fig1" ref-type="fig">Figure 1</xref>, <xref rid="fig2" ref-type="fig">2</xref>, <xref rid="fig5" ref-type="fig">5</xref>, <xref rid="fig6" ref-type="fig">6</xref>). Further supporting a role for Hsp70 in human AD pathology, we found that Hsp70 is upregulated in AD hippocampus and heavily intercalated within neuritic plaques and NFTs (<xref rid="fig7" ref-type="fig">Figure 7</xref>). The Hsp70 localization pattern was highly consistent in human AD hippocampus (<xref rid="figs8" ref-type="fig">Supplemental Figure 8</xref>) and illustrates a unique tau-Hsp70 pattern of co-pathology<sup><xref ref-type="bibr" rid="c59">59</xref>–<xref ref-type="bibr" rid="c61">61</xref></sup>. The lack of complete colocalization suggests that Hsp70 recruitment to tau occurs in a time-dependent manner. At least in a mature tau aggregation model, these data are consistent with Hsp70 stabilizing a misfolded tau conformation that potentially evades proper triage and/or degradation.</p>
<p>In addition to Hsp70, tau is also an Hsp90 substrate, which competes for binding sites within tau’s MTBR and is thought to promote CHIP-mediated tau degradation and clearance<sup><xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c62">62</xref>–<xref ref-type="bibr" rid="c67">67</xref></sup>. It is plausible that aggregated tau may form as a consequence of an imbalance in the ratio of Hsp70 vs. Hsp90 binding, which, if shifted towards Hsp70, could radically shift tau processing away from degradation towards stabilization of aggregated tau intermediates. In this scenario, Hsp70 depletion or inhibition would facilitate proteasome or autophagic targeting (degradation) by shifting the balance away from tau refolding. Future proteomics studies will be needed to determine whether distinct tau triage complexes emerge temporally in response to tau aggregation. For example, identifying the PL-SF interactome over time may reveal distinct triage stages in which Hsp70 has shifted from pro-folding to pro-aggregation<sup><xref ref-type="bibr" rid="c19">19</xref></sup>.</p>
<p>We did not observe any effect of Hsc70 on tau aggregation. Though highly homologous, Hsc70 is constitutively expressed at ∼30-fold higher levels in the brain compared to the inducible Hsp70 isoform<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. Hsp70, but not Hsc70, overexpression increased the number of MC1-positive neurons by nearly 3-fold (<xref rid="fig3" ref-type="fig">Figure 3E, F</xref>). Since Hsp70 is more sensitive to redox signaling (via cysteine residue reactivity), its activity towards tau may be more tunable under stress conditions<sup><xref ref-type="bibr" rid="c68">68</xref></sup>. Prior work has shown that the functional outcome of Hsp70-tau interactions is highly dependent on the specificity and fine-tuning provided by co-chaperones that regulate Hsc70<sup><xref ref-type="bibr" rid="c34">34</xref></sup>, Hsp90<sup><xref ref-type="bibr" rid="c69">69</xref>–<xref ref-type="bibr" rid="c71">71</xref></sup>, CHIP<sup><xref ref-type="bibr" rid="c16">16</xref></sup>, as well as small heat shock proteins<sup><xref ref-type="bibr" rid="c72">72</xref>–<xref ref-type="bibr" rid="c74">74</xref></sup>. Thus, we suspect that many variables could dictate how effectively and efficiently Hsp70 targets tau, including: 1) the extent of MT-dissociated aggregated tau present, 2) the relative balance and abundance of chaperones, co-chaperones, and cofactors that target and triage tau, and 3) the notion that disease onset and disease progression (either acute or chronic) may involve distinct signaling pathways or compensatory responses.</p>
<p>Taken together, our study supports the notion that depletion or activity-modifying approaches targeting Hsp70 (or its cofactors and co-chaperones) may be neuroprotective in the context of the AD brain. While brain-specific HSP70 knockout mice are not available (to the best of our knowledge), brain-permeable Hsp70 inhibitors may have therapeutic utility, although broad Hsp70 inhibition could have detrimental effects on overall brain proteostasis. Therapeutic strategies aimed at “precision proteostasis” could selectively modulate chaperone–client interactions to favor the clearance of pathogenic tau without compromising global protein homeostasis and without directly targeting tau itself.</p>
</sec>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Plasmid and lentivirus cloning</title>
<p>To generate the pUltra-T40 WT, PL, PL-SF, SF, PL/SF-2Δ (277-278), PL/SF-2Δ (308-309), PL/SF-4Δ, HSC70-flag, HSP70-flag, and HSP90-flag constructs, the cDNAs were amplified through PCR and inserted into the pUltra vector using AgeI and SalI restriction endonucleases to replace eGFP in pUltra. pUltra-XeGFP was made by removing eGFP using AgeI and BspEI, creating a blunt end with Klenow before circularizing. pUltra-T40 WT (eGFP), PL/SF (eGFP), and PL/SF-4Δ (eGFP) were created by replacing TDP43 in pUltra TDP43 WT (eGFP) using BspEI and SalI. To generate PL/SF/2IP, two consecutive Q5 site-directed mutagenesis were performed on PL/SF(eGFP). pUltra was ordered from Addgene (Plasmid #24129). pUltra was a gift from Malcolm Moore (Addgene plasmid # 24129; <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:RRID:Addgene_24129">RRID:Addgene_24129</ext-link>). shRNA plasmids against HSP70 (TRCN0000098597, TRCN0000098598) and HSP90 (TRCN0000008491, TRCN0000008494) were ordered from the UNC Lenti-shRNA Core Facility. Primers used for vector construction are in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title>Primers used for vector construction</title></caption>
<graphic xlink:href="636933v3_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s4b">
<title>QBI-293 cell culture</title>
<p>QBI-293 (HEK293A) cells (ThermoFisher, #R70507) are commercially available and maintained according to standard protocols. QBI-293 cells were cultured in complete DMEM media (10% fetal bovine serum, 1X L-glutamine, and 1X penicillin/streptomycin). QBI-293 cells were transfected with FuGENE 6 transfection reagent (Promega) to express 2N4R tau constructs for 48 hr. Following transfection, cells were lysed and collected in 1X RIPA buffer [50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholate, 1% Igepal CA-630, 0.1% SDS] supplemented with deacetylase, phosphatase and protease inhibitors: 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM Nicotinamide (NCA), 1 mM sodium orthovanadate (Na3VO4), 1 mM sodium fluoride (NaF), 0.5 M β-glycerophosphate, 2 μM Trichostatin A (TSA), and protease inhibitor cocktail composed of L-1-tosylamide-2-phenylethylchloromethyl, N-tosyl-L-lysine chloromethyl ketone, leupeptin, pepstatin, and soybean trypsin inhibitor, each at 1 μg/ml.</p>
</sec>
<sec id="s4c">
<title>Primary cortical neuron cell culture</title>
<p>Mouse primary cortical culture was performed in accordance with the University of North Carolina (UNC) Institutional Animal Care and Use Committee (UNC IACUC protocol 24-190). Mouse cortical neurons were dissected and isolated from C57Bl/6 mice (Charles River) at embryonic day 15-16 following lethal isoflurane anesthesia. Following anesthesia, embryos were removed from the pregnant abdominal cavity, washed well with ice-cold 70% ethanol and placed in cold Hanks-buffered balanced salt solution (HBSS). Once rinsed, these embryos were moved to a 10cm dish for dissection. The embryos were then removed from the placental membrane and brains were isolated. The cortex was dissected then moved to Hibernate-E solution (BrainBits) with B27 (Gibco) and Glutamax (ThermoFisher). The cerebral cortices were minced thoroughly with forceps and incubated for 30 minutes at 37 °C in HBSS with 20 U/mL papain (Worthington Biomedical), 1mM EDTA, 0.2 mg/mL L-Cysteine, and 5U/mL DNAse (Promega). Cortical tissue was further dissociated in plating media (BrainPhys media (Stemcell), 5% fetal bovine serum, 1X B27 (Gibco), 1X penicillin/streptomycin (Gibco), and 1X Glutamax by triturating the sample using a P1000 micropipette. This suspension was centrifuged for 5 minutes at 1.5 rcf to pellet the cells. The pellet was then resuspended in plating media and passed through a 40 μm cell strainer. A Countess 3 automated cell counter (Invitrogen) was used to count the cells. Cells were plated in plating media at 600,000 cells/well in 6-well plates or 30,000 cells/well in 96-well plates. The next day (DIV1), plating media was completely aspirated and replaced with fresh neuronal media (BrainPhys media (Stemcell), B27 (Gibco), 1X penicillin/streptomycin (Gibco), and 1X Glutamax).</p>
</sec>
<sec id="s4d">
<title>Lentiviral production</title>
<p>Lentiviral production was performed by co-transfecting 37.5 mg lentivirus plasmid with 25 mg psPAX2, 12.5 mg VSVG, and 6.25 mg REV plasmids per 15 cm culture plates of Lenti-X 293 T cells (Takara). For each lentiviral construct, three 15 cm plates were used for production. Roughly 48 hrs after the transfection, cell culture media was collected and subsequently centrifuged at 2000 rcf for 10 minutes. Lentiviral particles were purified using a double-sucrose gradient method as follows: supernatants were loaded onto a 70–60% to 30–20% sucrose gradient and centrifuged at 70,000 rcf for 2 hr at 17 °C. The 30–60% fraction containing the viral particles was retrieved, resuspended in PBS, filtered with a 0.45 mm filter flask, loaded onto a 20% sucrose solution, and centrifuged a second time at 70,000 rcf for 2 hr at 17 °C. The supernatants were carefully discarded, and the viral particles in the pellet were resuspended in PBS, aliquoted and stored at − 80 °C.</p>
</sec>
<sec id="s4e">
<title>Lentiviral transductions</title>
<p>Primary neurons were transduced with ∼3.0×10<sup>12</sup> viral particles per mL at DIV4 for most experiments (viruses were added at DIV18 for MEA experiments). If neurons were co-transduced with two viruses, both were added sequentially (each at ∼3.0×10<sup>12</sup> viral particles per mL). For transductions, viruses were added directly to the media in each well (1 µl virus per 2 mL media), followed by gentle rocking by hand to distribute viral particles. The following day, virus-containing media was completely aspirated and replaced with half conditioned media (neuronal media from the same neuron culture) and half fresh neuronal media (BrainPhys (StemCell) with B27 (Gibco), Pen-strep (Gibco), and Glutamax (Gibco)). Every two-three days, half of the neuronal media was discarded and replenished with fresh neuronal media until neurons were collected. Most neurons were collected at DIV10 (7 days after transduction), unless otherwise noted.</p>
</sec>
<sec id="s4f">
<title>Immunoblotting and biochemical analysis</title>
<p>RIPA soluble lysates (250 µl per well of a 6-well plate) collected from QBI-293 and primary cortical neuron were sonicated 20 times on ice, then centrifuged at 15,000 rcf for 20 minutes at 4 °C. The supernatant was removed from the pelleted material, leaving behind a RIPA insoluble pellet. The RIPA insoluble pellet was washed with 250 µl of RIPA lysis buffer with protease, phosphatase, and deacetylase inhibitors and centrifuged at 15,000 rcf for 20 minutes at 4 °C. This supernatant was removed and discarded and 75 µl of 1% SDS was added to each pellet then sonicated 20 times at room temperature. These samples were then centrifuged at 15,000 rcf at room temperature. The supernatant from these tubes was removed and stored in separate tubes as the SDS-soluble fraction. The RIPA and SDS-soluble supernatants were then mixed with 6X loading dye with DTT and boiled at 98 °C for 10 minutes in a PCR thermocycler (BioRad). Samples were run and resolved via SDS-PAGE on 4–20% gradient gels (BioRad). Gels were transferred to iBlot 2 Midi nitrocellulose membranes using the iBlot 2 (Invitrogen) following the standard P0, 7-minute settings. Following transfer, membranes were blocked with 2% milk in 1X TBS for 30 minutes and then incubated with primary antibody overnight at 4 °C on a rocker. The next day, membranes were incubated with HRP-conjugated anti-mouse or anti-rabbit antibodies (1:1000) for 1-2 hr at room temperature. Blots were developed with ECL Western Blotting substrate (Cytiva, Amsterdam) and imaged on a GE ImageQuant LAS4000.</p>
</sec>
<sec id="s4g">
<title>Immunocytochemistry</title>
<p>Immunocytochemistry experiments were performed using QBI-293 cells or cortical primary neurons plated on poly-D-lysine (PDL)-coated 96-well plates. Following either plasmid transfection (48 hr) or lentiviral transduction (7 days unless otherwise stated), cells were washed once in PBS, immediately fixed in 4% paraformaldehyde for 15 minutes, then washed once more with PBS. Following fixation, cells were then permeabilized with permeabilization buffer (0.2% Triton X-100 (Sigma) in PBS) for 20 minutes then blocking buffer (4% normal goat serum in PBS with 0.05% Tween 20) for 1 hr. Primary antibodies were added in blocking buffer and incubated overnight on a rocker at 4 °C. The following day, cells were washed 3X in PBS with 0.05% tween 20 and incubated with Alexa 488, Alexa 594, or Alexa 647 conjugated secondary antibodies at 1:1000 and DAPI for 1 hr. Cells were then washed 3X in PBS with 0.05% Tween 20. Cells were then imaged using an EVOS M7000 automated microscope with EVOS 20X objective (Invitrogen AMEP4982) and 40X objectives (Invitrogen AMEP4754) and DAPI, GFP, Texas Red, and Cy5 light cubes. Note: Some representative images were artificially brightened or contrasted in Microsoft PowerPoint or Celleste 5.0 and 6.0 software (Invitrogen) to aid visualization. Any panels assessing the same set of conditions were brightened to identical levels. Images were not manipulated prior to quantification.</p>
</sec>
<sec id="s4h">
<title>Antibodies</title>
<p>The following primary antibodies were used in this study: AT8 (ThermoFisher Scientific-MN1020), AT100 (ThermoFisher Scientific MN1060), AT180 (ThermoFisher Scientific MN1040), TauC3 (ThermoFisher Scientific-AHB0061), T49 mouse tau (Millipore-MABN827), Tau12 (Millipore, MAB2241, 1:1000), Tau5 (AHB0042), Hsp70 used for immunoblotting (Enzo-ADI-SPA-810-D), Hsp70 used for immunoblotting and immunocytochemistry (Cell Signaling Technologies-4872), Hsc70 1B5 (ADI-SPA-815-F), Hsp90 16F1 (Enzo-adi-spa-835), Total tau rabbit polyclonal-formerly K9JA (DAKO, A0024 1:2000), GAPDH 6C5 (Millipore-MAB374), ac-tubulin (Sigma T7451), alpha tubulin (Sigma, T9026), Anti-FLAG M2 (Sigma, F1804, 1:2000), GFAP (Dako, 20334). The MC1 antibody was kindly shared by Dr. Peter Davies. Quantification of immunoblotting was measured by ImageStudio Lite Version 5.2.</p>
</sec>
<sec id="s4i">
<title>Co-immunoprecipitation reactions</title>
<p>All co-immunoprecipitations were performed in QBI-293 cells transfected with plasmids expressing 2N4R wild-type, P301L, P301L/S320F, and P301L/S320F 4Δ for 48 hrs prior to collection. Each well of a 6-well plate was used as separate conditions. Cells were collected in 250 µl RIPA buffer with protease, phosphatase, and deacetylase inhibitors prior to co-immunoprecipitation. Lysates were immediately rotated on a wheel for 30 minutes at 20 rpm at 4 °C. Lysates were then centrifuged at 15,000 rcf for 15 minutes at 4 °C. Supernatants were removed and 40 µl were kept as input. The remaining supernatant was pre-cleared with 50 µl of Protein A/G PLUS-Agarose beads (Santa Cruz, sc2003) for 30 minutes at 4 °C. Lysates were centrifuged for 1 minute at 1,500 rcf, and the supernatant was removed. The volume of each reaction was brought to 500 µl of RIPA buffer with inhibitors. For each reaction, 8 µl of tau5 antibody was added to each reaction, then 75 µl of agarose protein A/G beads. Lysates were rotated on a wheel at 20 rpm at 4 °C overnight. The following day, lysates were centrifuged at 1,500 rcf for 5 minutes. Most of the supernatant was carefully removed, followed by washing with 500 µl of RIPA buffer with inhibitors, and lysates were centrifuged at 1,500 rcf for 5 minutes. This wash was repeated four times. After the final wash, loading dye with DTT was directly added to the beads and heated for 10 minutes at 98 °C with intermittent mixing. These were centrifuged for 30 seconds at 1,500 rcf prior to storage at -80 °C.</p>
</sec>
<sec id="s4j">
<title>Purification of recombinant tau</title>
<p>Tau purification methods were adapted from Barghorn et al, 2004<sup><xref ref-type="bibr" rid="c75">75</xref></sup>. Untagged wild-type and mutant versions of tau were cloned into pRK172 backbone and transformed into BL21(DE3)-RIL cells. Cells were grown in LB media at 37 °C until the OD600 reached 0.8. Protein expression was then induced with IPTG and continued shaking at 37 °C for 3-5 hrs. After the cells were harvested and resuspended in lysis buffer (20 mM MES pH 6.8, 1 mM EDTA, 5 mM DTT, protease inhibitors benzamidine and leupeptin, and PMSF), the cells were lysed via sonication. Lysed cells were heat shocked at 80 °C for 20 minutes, then centrifuged at 17,500 rpm (36,635 xg) for 30 minutes to remove cell debris. Clarified lysate was dialyzed overnight at 4 °C into wash buffer (20 mM MES pH 6.8, 50 mM NaCl, 1 mM EDTA, 1 mM MgCl<sub>2</sub>, 2 mM DTT). Following overnight dialysis, lysates were centrifuged at 17,500 rpm (36,635 xg) for 30 minutes to remove precipitated proteins and then subjected to cation exchange chromatography. The protein was eluted by increasing salt concentration in buffer to 250 mM. The samples were further purified via size exclusion chromatography on a Superdex 200 Increase 10/300 GL column in sizing buffer (25 mM HEPES pH 7.5, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, 1 mM DTT). Samples were then concentrated as needed using centrifugal filters and flash frozen for later use.</p>
</sec>
<sec id="s4k">
<title>Heparin-induced tau aggregation assays</title>
<p>Tau aggregation assays were carried out in a PolarStar Omega microplate reader using Thioflavin T (ThT) fluorescence to monitor formation of tau aggregates. Aggregation reactions were started by combining 5 µM tau, 2 µM heparin, and 20 µM ThT in reaction buffer (1x PBS, 2 mM TCEP) and transferred to a costar 96-well half-area microplate (black polystyrene, flat bottom, non-treated). The microplate was covered with an ELISA plate sealer and placed in the microplate reader at 37 °C. Fluorescence measurements were taken every 5 minutes for 12 hrs using a 440-10 nm excitation and 485-12 nm emission filter.</p>
</sec>
<sec id="s4l">
<title>HSP70 and HSP90 shRNA knockdown</title>
<p>All shRNAs were obtained from UNC Lenti-shRNA core facility and cloned into the pUltra vectors. Sequences: HSP70 shRNA: GCAGGTGAACTACAAGGGCGA; eGFP control shRNA: TACAACAGCCACAACGTCTAT (Y145 to Y151 residues of eGFP). HSP70 shRNAs were added to the neuron culture four days after transduction with tau lentiviruses at a titer of ∼3.0×10<sup>12</sup> viral particles per mL. Media was half exchanged for fresh neuronal media every two days. After an additional four days in culture, primary neurons lysates were collected for experiments. We noted some toxicity after more than 4 days in culture with HSP70 shRNAs. HSP90 shRNAs were applied for 7 days in culture (∼3.0×10<sup>12</sup> viral particles per mL) prior to collection for experiments and were not overtly toxic.</p>
</sec>
<sec id="s4m">
<title>Multi-electrode array recordings and analysis</title>
<p>Following dissection, primary mouse cortical neurons were directly plated onto poly-D lysine coated 24-well BioCircuit MEA plates (Axion Biosystems). A 10 µl droplet of neurons at a concentration of 16,000,0000 neurons/mL was added directly to the center of each well. Neurons were incubated at 37 °C for 1 hr then 250 µl of plating media (BrainPhys media (Stemcell), 5% fetal bovine serum, 1X B27 (Gibco), 1X penicillin/streptomycin (Gibco), and 1X Glutamax) was carefully added to each well in a circular motion. Following another 1-hr incubation, another 250 µl of plating media was added to each well (total volume = 500 µl). The following day, ∼90% of plating media was aspirated and fresh neuronal (BrainPhys media (Stemcell), B27 (Gibco), 1X penicillin/streptomycin (Gibco), and 1X Glutamax) media was added to each well. Half of the media was exchanged for fresh neuronal media every two days. At DIV18, neurons underwent an initial, 10-minute pre-recording using the Axion Maestro Edge (Axion Biosystems) and AxIS Navigator software (Axion Biosystems). Immediately following this recording, neurons were transduced with lentiviruses at ∼3.0×10<sup>12</sup> viral particles per mL (four replicate wells per condition). The following day, neuronal activity was recorded for 10 minutes, then lentivirus-containing neuronal media was completely replaced with half fresh neuronal media and half conditioned neuronal media from the same culture. Neurons were recorded nearly every day for 10 minutes and half of the neuronal media was replaced every 2-3 days after recording until DIV71 (day 53 of recording). Post-hoc analysis was performed using the NeuralMetricTool (Axion Biosystems) using default analysis options. Data was exported into Microsoft Excel, then graphed via GraphPad Prism 10 for statistical analyses and graphing. Raster plots were generated from the same data using the AxIS Metric Plotting Tool. 96 well plates were plated at the same time using the same primary neurons, underwent identical media changes, and were used for immunocytochemistry at DIV29 and DIV62 in <xref rid="fig5" ref-type="fig">Figure 5</xref>.</p>
</sec>
<sec id="s4n">
<title>Post-synaptic density isolation</title>
<p>Primary mouse cortical neurons from wild-type C57/BL6 mice were plated on poly-D-lysine coated 6-well plates at 600,000 cells/well. Neurons were treated with lentivirus at DIV4 (1 6-well plate per condition) and half-fed every two days until DIV14. At DIV14, neurons were rinsed in cold PBS and all 6-wells of each plate were collected in a total of 900 µl of homogenization buffer (320 mM sucrose, 5 mM sodium pyrophosphate, 1 mM EDTA, 10 mM HEPES pH 7.4) with protease/phosphatase inhibitor cocktail 200 nM okadaic acid, 1 mM orthovanadate, 1X protease inhibitor cocktail (Roche). Neuronal lysates were homogenized by passing the lysate 12 times using a 26g needle. For each condition, 70 µl of lysate was kept and stored as whole cell lysate. The remaining lysate was centrifuged at 1,000 g for 10 minutes at 4 °C <italic>to</italic> generate pelleted nuclear fraction (P1) and supernatant fraction (S1). The S1 fraction was centrifuged at 15,000 g for 20 minutes at 4 °C to generate the membrane/crude synaptosome pelleted fraction (P2) and cytosolic supernatant fraction (S2). The P2 fraction was resuspended in 500 µl of ultrapure H<sub>2</sub>0 with protease/phosphatase cocktail. 20 µl of 100 mM HEPES was added to the 500 µl of suspension to yield 4 mM HEPES pH 7.4. These samples were then spun on a wheel for 30 minutes at 4°C then centrifuged for 20 minutes at 4 °C at 25,000 g using a Sorvall mTX 150 ultracentrifuge (Thermo Scientific) to generate pelleted synaptic fraction (LP1) and supernatant fraction (LS2). The LP1 pellet was resuspended in 250 µl mM HEPES pH7.4 using repeated trituration with a micropipette. This was then mixed with 250 µl of 1% Triton X-100 with protease/phosphatase cocktail and spun on a wheel for 10 minutes at 4 °C. This was then centrifuged in Sorvall mTX 150 ultracentrifuge (Thermo Scientific) at 32,000 g for 20 minutes at 4 °C. This pellet was resuspended in 80 μL of 50 mM HEPES pH7.4 using micropipette trituration to yield the PSD fraction. Only total homogenate and PSD fraction were processed and analyzed by SDS-PAGE.</p>
</sec>
<sec id="s4o">
<title>Imaging quantification</title>
<p>All immunocytochemistry (aside from organotypic slice cultures) quantification was performed using Celleste 5.0 and 6.0 software (Invitrogen). The number of inclusions were counted using the count/size function. Puncta and inclusions were manually segmented based on intensity (Segment: Manual) and size (Region: Area) thresholds for each tau probe (e.g. AT8, MC1, ThioS). These threshold settings were then applied to all images used for that specific experiment, automatically batched processed using a segment-count-export macro generated in Celleste, then exported to Microsoft Excel for subsequent analysis.</p>
</sec>
<sec id="s4p">
<title>Hippocampal slice cultures</title>
<p>Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were housed and maintained in accordance with the recommendations from the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health, and in accordance with an approved protocol from the Institutional Animal Care and Use Committee of the University of North Carolina-Pembroke. Brain tissue from postnatal 12-day-old rats was rapidly prepared and hippocampi positioned on a McIlwain tissue chopper for assembling slices for interface cultures as previously described<sup><xref ref-type="bibr" rid="c76">76</xref>,<xref ref-type="bibr" rid="c77">77</xref></sup>. Three-dimensional organotypic cultures of specific brain regions are well known for studying different types of physiologies and pathogenic processes<sup><xref ref-type="bibr" rid="c78">78</xref>–<xref ref-type="bibr" rid="c80">80</xref></sup>. Transverse hippocampal slices (400-µm thickness) were immediately placed in ice-cooled-buffer solution (pH 7.2) then transferred in groups of eight to nine onto the Biopore membrane of culture inserts (Millipore, Billerica, MA). The media below the culture inserts contained 50% basal medium eagle (Sigma-Aldrich, St. Louis, MO), 25% Earle’s balanced salts (Sigma-Aldrich), 25% horse serum (Gemini Bio-Products, Sacramento, CA), and defined supplements as previously described<sup><xref ref-type="bibr" rid="c81">81</xref></sup>. The media were initially changed 24 hrs after the slicing procedure, followed by subsequent changes every 3-4 days. The cultivated hippocampal slices were maintained under conditions of a 5% CO2-enriched atmosphere at a constant temperature of 37 °C for a duration of nine weeks.</p>
</sec>
<sec id="s4q">
<title>Lentiviral infection of organotypic cultures</title>
<p>Lentiviruses expressing GFP or GFP-tagged tau variants (wild-type, PL-SF, and PL-SF 4Δ tau). For each condition, 1.5 µl of lentivirus were applied onto the surface of individual organotypic slices (∼7.5×10<sup>12</sup> viral particles per slice) approximately 3 hrs after the placement of the slices on Millipore inserts. Following a nine-week incubation period in vitro, both the infected organotypic slices and their corresponding controls were fixed with 4% PFA for 3-4 hrs. Subsequently, the slices were rinsed multiple times with PBS and stored in PBS at 4 °C.</p>
</sec>
<sec id="s4r">
<title>Immunofluorescence staining and imaging of organotypic brain slice cultures</title>
<p>The fixed organotypic hippocampal explants underwent permeabilization in PBS containing 0.5% Triton-X100 for 30 minutes. Following this, the slices were blocked with a solution of 5% BSA in PBS containing 0.1% Triton-X100 for 90 minutes at room temperature. Subsequently, the organotypic slices were incubated for 48 hrs at 4 °C with primary antibodies targeting AT8 (1/400; ThermoFisher Scientific-MN1020) or MC1 (1/400; Dr. Peter Davies, diluted in a solution of 3% BSA containing 0.1% Triton-X100. Next, brain explants were washed 3-4 times with PBS containing 0.1% Triton-X100 and then exposed to Goat anti-mouse IgG Alexa-FluorTM 568 (ThermoFisher, Waltham, MA) for 120 minutes at room temperature. Following this incubation, the organotypic slices were rinsed three times with PBS containing 0.1% Triton-X100. During the second wash, NucBlue stain (Invitrogen, MA, USA) was introduced to the PBS to promote DAPI nuclear staining. Subsequently, the slices were rinsed in PBS and were mounted onto glass slides, covered by 1.5 mm coverslips, using ProlongTM diamond antifade mountant (Thermo Fisher Scientific, NC, USA). Immunofluorescence images were captured with Andor Dragonfly spinning disk confocal using the Zyla Plus 4.2MP sCMOS (Oxford Instruments, Abingdon, United Kingdom). Image our blinded processed adopting the equal adjust using the Imaris Multidimensional visualization and analysis software (Schlieren-Zurich, Switzerland).</p>
</sec>
<sec id="s4s">
<title>Human brain fractionation</title>
<p>Human control and Alzheimer’s disease (AD) cortical brain tissues (Braak stages V–VI) were obtained from the Center for Neurodegenerative Disease Research brain bank at the University of Pennsylvania. Gray matter from the frontal cortex of each subject was isolated and homogenized in 3 volumes per gram (vol/g) of cold high-salt RAB buffer (0.75 M NaCl, 100 mM Tris, 1 mM EGTA, 0.5 mM MgSO₄, 0.02 M NaF, 2 mM DTT, pH 7.4), supplemented with deacetylase, phosphatase, and protease inhibitors as previously described. Homogenates were incubated at 4 °C for 20 minutes to facilitate microtubule depolymerization, followed by ultracentrifugation at 100,000 × g for 30 minutes at 4 °C. The resulting supernatant was designated the high-salt fraction. The pellet was then re-homogenized and subjected to a second round of centrifugation under identical buffer and conditions. After removal of the supernatant, the remaining pellets were homogenized in 5 vol/g of cold RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS), and centrifuged once more at 100,000 × g for 30 minutes at 4 °C. Subsequent to myelin flotation, the pellets were re-extracted in RIPA buffer containing 20% sucrose to eliminate residual myelin and labeled as the RIPA fraction. Finally, the insoluble material was extracted using 1 vol/g of urea extraction buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5). Both the high-salt and urea-soluble fractions were subjected to SDS-PAGE followed by immunoblotting with antibodies targeting Hsp70, Hsc70, and GAPDH.</p>
</sec>
<sec id="s4t">
<title>Human brain immunohistochemistry and confocal microscopy</title>
<p>Human hippocampal tissue sections mounted on coverslips were obtained from the UNC Translational Pathology Laboratory (TPL), which oversees a cataloged and archived repository of Alzheimer’s disease (AD) brain specimens, including neuropathologically confirmed cases from UNC-affiliated donors. The 10 um sections were de-paraffinized with two 45-minute washes in xylene followed by one-minute washes in 100% ethanol (x2), 95% ethanol, 80% ethanol, 75% ethanol, water, and finally allowed to soak O/N in 1x PBS. Antigen retrieval is performed using a citrate-based antigen unmasking solution (Vector Labs, H-3300-250) in boiling Mill-Q water for 10-minutes. The slides were then washed 3×5-min with TBS, followed by 1x wash in TBS + 0.1% TritonX-100 for 20 minutes, 3×5-min with TBS, and 1×5 min in 3% Goat Serum in TBS (Southern Biotech, 0060-01). Sections were then stained 2x O/N in a humidified chamber at room temperature using anti-AT8 (1:500, Invitrogen, MN1020) and anti-Hsp70 (1:500, Abcam, ab181606). Slides were then washed 3×5-min with TBS followed by secondary staining with goat anti-mouse IgG 488 (1:1000, Invitrogen, A-11001) and goat anti-rabbit IgG 594 (1:1000, Invitrogen, A-11012) for 24 hours at 4°C in a dark, humidified chamber. Slides were then washed 3×5-min with TBS, allowed to dry, and mounted with Fluoromount-G with DAPI (Invitrogen, 00-4959-52).</p>
<p>Confocal microscopy was performed on an LSM980 (Zeiss) inverted laser scanning confocal microscope. The LSM980 is equipped with a motorized X, Y, stage and Z-focus with high-speed Piezo insert along with four diode lasers (405, 488, 561, and 633). Images were acquired with 1x Nyquist sampling using 63x 1.4 NA Plan-Apochromat oil objective (Zeiss) and 4 channel GaAsP detectors on Zen Blue 3.6 software. Images were acquired with 1x Nyquist sampling using 20×0.8 NA Plan-Apochromat air objective (Zeiss) and 4 channel GaAsP detectors on Zen Blue 3.6 software.</p>
</sec>
<sec id="s4u">
<title>Statistical analysis</title>
<p>GraphPad Prism 10 software was used for all statistical analyses. For comparisons between two groups, two-tailed unpaired Student’s t-tests were used. For multiple group comparisons, one-way ANOVA followed by Dunnet’s or Sidak’s post hoc tests were applied as appropriate. Results were polled from a minimum of n=3 independent experiments and presented as mean ± standard error of the mean (SEM). P-values &lt; 0.05 were considered statistically significant. The number of replicates (n) and details of the specific tests applied are provided in figure legends.</p>
</sec>
</sec>
</body>
<back>
<sec id="das" sec-type="data-availability">
<title>Data availability</title>
<p>All data is present within main and supplemental figures.</p>
</sec>
<sec id="s8" sec-type="supplementary">
<title>Supplemental Figures</title>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 1:</label>
<caption><title>Accelerated PL-SF aggregation compared to single tau mutants in immortalized cell lines.</title>
<p><bold>A)</bold> Representative immunocytochemistry images from QBI-293 cells expressing empty vector (pcDNA) or WT, PL, SF, and PL-SF tau variants. Cells were labeled with AT8 (p-tau) or TauC3 (C-terminal cleaved tau) with rabbit polyclonal tau (total tau) and ThioS with Tau12 (human tau). Quantification of images is found in <xref rid="fig1" ref-type="fig">Figure 1C</xref>. Control= empty plasmid vector (pcDNA3.1). Scale bar= 125 µm.</p></caption>
<graphic xlink:href="636933v3_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 2:</label>
<caption><title>Immunoblotting analysis of a panel of P301 and S320 single and combination mutants.</title>
<p><bold>A-G)</bold> Quantification of AT8, MC1, TauC3, and ThioS immunocytochemistry in QBI-293 cells expressing various P301 and S320 mutants alone or in combination. Panels E-G are subsets of data from A-C to perform additional comparisons among combinatorial mutants. Representative images not shown. Error bars= SEM. *= significant difference by one-way ANOVA. <bold>H)</bold> Representative immunoblots from QBI-293 cells expressing wild-type, P301S/S320F, P301T/S320F, and P301L/S320F tau variants. RIPA (soluble) and urea (insoluble) fractions were analyzed by immunoblotting for p-tau epitopes (AT8, AT180, AT270, p-396) and total tau (rabbit polyclonal). <bold>I, J)</bold> Quantification of RIPA soluble and urea (insoluble) fractions. Error bars= SEM. *= significant difference by one-way ANOVA.</p></caption>
<graphic xlink:href="636933v3_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 3:</label>
<caption><title>Abrogating Hsp binding via the PL-SF 4Δ variant suppresses the accumulation of pathological tau.</title>
<p>Representative immunocytochemistry images from QBI-293 cells expressing tau PL-SF and PL-SF 4Δ tau variants. Cells were probed with AT8 (p-tau), TauC3 (C-terminal cleaved tau) with rabbit polyclonal tau (total tau), and ThioS with Tau12 (human tau). Quantification of images is found in <xref rid="fig1" ref-type="fig">Figure 1F</xref>. Control= empty plasmid vector (pcDNA3.1). Scale bar= 125 µm.</p></caption>
<graphic xlink:href="636933v3_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 4:</label>
<caption><title>PLSF containing the β-structure breaking mutations, I277P/I308P, prevents tau aggregation similar to PLSF 4Δ.</title>
<p><bold>A)</bold> Representative RIPA immunoblot of primary neurons transduced with empty control, PLSF 4Δ-eGFP, PLSF I277P/I308P (2IP), or PLSF-eGFP and probed for p-tau (AT8) and total tau (rabbit polyclonal). <bold>B)</bold> Quantification of AT8 and total tau in RIPA fraction. <bold>C)</bold> Representative SDS immunoblot of primary neurons transduced with empty control, PLSF 4Δ-eGFP, PLSF I277P/I308P (2IP), or PLSF-eGFP and probed for p-tau (AT8) and total tau (rabbit polyclonal. <bold>D)</bold> Quantification of SDS fraction. *= significant difference by one-way ANOVA.</p></caption>
<graphic xlink:href="636933v3_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 5:</label>
<caption><title>PL-SF aggregates emerge similarly in either wild-type or tau knockout neurons lacking endogenous mouse tau.</title>
<p><bold>A)</bold> RIPA (soluble) immunoblot of wild-type tau and tau knockout neurons probed with p-tau (AT8, AT180, AT100) and total tau (rabbit polyclonal). <bold>B)</bold> SDS (insoluble) immunoblot of wild-type tau and tau knockout neurons probed with p-tau (AT8) and total tau (rabbit polyclonal). <bold>C)</bold> Representative immunoblotting images of wild-type, P301L, S320F, and P301L/S320F tau variants in wild-tau-expressing or tau knockout neurons. Neurons were labeled with AT8 (GFP) and rabbit polyclonal total tau (RFP), MC1 (GFP), or ThioS (GFP) and Tau12 (RFP). Scale bar= 125 µm. Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 6:</label>
<caption><title>Overexpression of HSP70 in P301L-expressing neurons does not promote tau phosphorylation or aggregation.</title>
<p><bold>A)</bold> RIPA (soluble) immunoblot of primary neurons following 1-week of lentiviral co-transduction with P301L tau and HSP70. Blot was probed with p-tau (AT8), total tau (rabbit polyclonal), and M2 FLAG (Hsp70-FLAG). <bold>B)</bold> SDS (insoluble) immunoblot of primary neurons was unable to detect insoluble tau species with total tau antibody (rabbit polyclonal). Control= empty viral vector (pUltra).</p></caption>
<graphic xlink:href="636933v3_figs6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 7:</label>
<caption><title>HSP90 depletion does not alter phosphorylated or aggregated PL-SF tau.</title>
<p><bold>A)</bold> RIPA (soluble) immunoblot of primary neurons probed with p-tau (AT8) and Hsp90 following 1-week of lentiviral HSP90 knockdown with two shRNAs (called TRC91 and TRC94). <bold>B)</bold> SDS (insoluble) immunoblot of primary neurons probed with p-tau (AT8) and total tau (rabbit polyclonal) following 1-week of lentiviral HSP90 knockdown. <bold>C)</bold> Quantification of AT8 and Hsp90 in the RIPA fraction. Error bars= SEM. <bold>D)</bold> Quantification of AT8 and total tau (rabbit polyclonal) in SDS fraction. *Note: Only TRC94, and not TRC91, HSP90 shRNA was able to reduce Hsp90 expression.</p></caption>
<graphic xlink:href="636933v3_figs7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs8" position="float" orientation="portrait" fig-type="figure">
<label>Supplemental Figure 8:</label>
<caption><title>Hsp70 foci accumulation within neuritic plaques and neurofibrillary tangles in human AD brain</title>
<p><bold>A)</bold> Representative stitched widefield images of a human AD patient hippocampus labeled with AT8 (GFP) and Hsp70 (RFP). AT8/Hsp70 positive plaques are labeled with white arrowheads. AT8/Hsp70 positive tangles are labeled with white arrows. * = a single AT8 positive tangle that is absent for Hsp70 foci.</p></caption>
<graphic xlink:href="636933v3_figs8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The Andor Dragonfly microscope was funded with support from National Institutes of Health grant S10OD030223. The Zeiss LSM 980 microscope was funded with support from NIH grant S10 OD032388. We would also like to thank Kinsley Adams for her expertise and assistance with the hippocampal organotypic slice cultures. We would also like to thank the University of Pennsylvania (Center for Neurodegenerative Disease Research brain bank) for providing human control and AD cortex lysates. Lastly, we would like to thank the University of North Carolina Translational Pathology Laboratory for providing AD hippocampal brain sections.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Funding Declaration</title>
<p>Support for this work was provided by National Institutes of Health (NIH) grants F32AG072826 (MRB) and R01AG068063 (TJC). This study was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG072958 (NIAP30AG072958) (MRB, MA, and JHT), Alzheimer’s Association grants AARG-22-924321 (TJC) AARF22926617 (JHT), and CurePSP grant 656-2018-06 (TJC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>MRB designed and performed most experiments. MA, JS, and BB designed and carried out ex vivo organotypic slices experiments and imaging. KP performed all immunohistochemistry and confocal imaging of human post-mortem brain. CO assisted with co-immunoprecipitation experiments and post-synaptic density preparations. CO and JHT performed human brain fractionation and immunoblots. EP performed all protein purification and carried out the Thioflavin T aggregation assays. JMM assisted with multi-electrode array recordings and analyses. XT prepared all plasmid and lentiviral constructs for all experiments. DK and HT designed and performed the QBI293 experiments comparing various P301 and S320 tau mutants. JHT, JS, NB, and BB provided additional experimental guidance and interpretation. MRB and TJC prepared the manuscript and figures. TJC directed and supervised the study. All authors consented and contributed to the final version of the manuscript.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strang</surname>, <given-names>K. H.</given-names></string-name>, <string-name><surname>Golde</surname>, <given-names>T. E.</given-names></string-name> &amp; <string-name><surname>Giasson</surname>, <given-names>B. I</given-names></string-name></person-group>. <article-title>MAPT mutations, tauopathy, and mechanisms of neurodegeneration</article-title>. <source>Lab Investig</source>. <volume>99</volume>, <fpage>912</fpage>–<lpage>928</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanders</surname>, <given-names>D. W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</article-title>. <source>Neuron</source> <volume>82</volume>, <fpage>1271</fpage>–<lpage>88</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peeraer</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice</article-title>. <source>Neurobiol Dis</source>. <volume>73</volume>, <fpage>83</fpage>–<lpage>95</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clavaguera</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Transmission and spreading of tauopathy in transgenic mouse brain</article-title>. <source>Nat Cell Biol</source>. <volume>11</volume>, <fpage>909</fpage>–<lpage>913</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>FTD-tau S320F mutation stabilizes local structure and allosterically promotes amyloid motif-dependent aggregation</article-title>. <source>Nat Commun</source>. <volume>14</volume>, <fpage>1625</fpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosso</surname>, <given-names>S. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A noveltau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick’s disease</article-title>. <source>Ann Neurol</source> <volume>51</volume>, <fpage>373</fpage>–<lpage>376</lpage> (<year>2002</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trzeciakiewicz</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline</article-title>. <source>Nat Commun</source> <volume>11</volume>, <fpage>5522</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koller</surname>, <given-names>E. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy</article-title>. <source>Hum Mol Genet</source> <volume>28</volume>, <fpage>3255</fpage>–<lpage>3269</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strang</surname>, <given-names>K. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Distinct differences in prion-like seeding and aggregation between tau protein variants provide mechanistic insights into tauopathies</article-title>. <source>J Biological Chem</source> <volume>293</volume>, <fpage>2408</fpage>– <lpage>2421</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Croft</surname>, <given-names>C. L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies</article-title>. <source>J Exp Medicine</source> <volume>216</volume>, <fpage>539</fpage>–<lpage>555</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice</article-title>. <source>Commun Biology</source> <volume>5</volume>, <fpage>446</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beckman</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Temporal progression of tau pathology and neuroinflammation in a rhesus monkey model of Alzheimer’s disease</article-title>. <source>Alzheimer’s Dement</source>. <volume>20</volume>, <fpage>5198</fpage>–<lpage>5219</lpage> (<year>2024</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaniyappan</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments</article-title>. <source>Mol Neurodegener</source>. <volume>15</volume>, <fpage>39</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname>, <given-names>E. D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Tau from SPAM Transgenic Mice Exhibit Potent Strain-Specific Prion-Like Seeding Properties Characteristic of Human Neurodegenerative Diseases</article-title>. <source>NeuroMolecular Med</source>. <volume>27</volume>, <fpage>44</fpage> (<year>2025</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Croft</surname>, <given-names>C. L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions</article-title>. <source>Acta Neuropathol</source> <fpage>1</fpage>–<lpage>23</lpage> (<year>2021</year>) doi:<pub-id pub-id-type="doi">10.1007/s00401-021-02264-9</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jinwal</surname>, <given-names>U. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Imbalance of Hsp70 family variants fosters tau accumulation</article-title>. <source>FASEB J</source>. <volume>27</volume>, <fpage>1450</fpage>–<lpage>1459</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Voss</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Combs</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Patterson</surname>, <given-names>K. R.</given-names></string-name>, <string-name><surname>Binder</surname>, <given-names>L. I.</given-names></string-name> &amp; <string-name><surname>Gamblin</surname>, <given-names>T. C</given-names></string-name></person-group>. <article-title>Hsp70 Alters Tau Function and Aggregation in an Isoform Specific Manner</article-title>. <source>Biochemistry</source> <volume>51</volume>, <fpage>888</fpage>–<lpage>898</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jinwal</surname>, <given-names>U. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsc70 Rapidly Engages Tau after Microtubule Destabilization*</article-title>. <source>J Biol Chem</source> <volume>285</volume>, <fpage>16798</fpage>–<lpage>16805</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rutledge</surname>, <given-names>B. S.</given-names></string-name>, <string-name><surname>Choy</surname>, <given-names>W.-Y.</given-names></string-name> &amp; <string-name><surname>Duennwald</surname>, <given-names>M. L</given-names></string-name></person-group>. <article-title>Folding or holding?—Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease</article-title>. <source>J Biol Chem</source>. <volume>298</volume>, <fpage>101905</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrucelli</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation</article-title>. <source>Hum Mol Genet</source> <volume>13</volume>, <fpage>703</fpage>–<lpage>714</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname>, <given-names>A. D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Analysis of the Tau-Associated Proteome Reveals That Exchange of Hsp70 for Hsp90 Is Involved in Tau Degradation</article-title>. <source>ACS Chem Biol</source>. <volume>7</volume>, <fpage>1677</fpage>–<lpage>1686</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fontaine</surname>, <given-names>S. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Isoform-selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement*</article-title>. <source>J Biol Chem</source> <volume>290</volume>, <fpage>13115</fpage>–<lpage>13127</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Young</surname>, <given-names>Z. T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy</article-title>. <source>Cell Chem Biol</source>. <volume>23</volume>, <fpage>992</fpage>–<lpage>1001</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pratt</surname>, <given-names>W. B.</given-names></string-name>, <string-name><surname>Gestwicki</surname>, <given-names>J. E.</given-names></string-name>, <string-name><surname>Osawa</surname>, <given-names>Y.</given-names></string-name> &amp; <string-name><surname>Lieberman</surname>, <given-names>A. P</given-names></string-name></person-group>. <article-title>Targeting Hsp90/Hsp70-Based Protein Quality Control for Treatment of Adult Onset Neurodegenerative Diseases</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <volume>55</volume>, <fpage>353</fpage>–<lpage>371</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dickey</surname>, <given-names>C. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins</article-title>. <source>J Clin Invest</source> <volume>117</volume>, <fpage>648</fpage>–<lpage>658</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models</article-title>. <source>Pharmacol Res</source>. <volume>189</volume>, <fpage>106692</fpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents</article-title>. <source>Acs Med Chem Lett</source> <volume>4</volume>, <fpage>1042</fpage>–<lpage>1047</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyata</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Synthesis and Initial Evaluation of YM-08, a Blood-Brain Barrier Permeable Derivative of the Heat Shock Protein 70 (Hsp70) Inhibitor MKT-077, Which Reduces Tau Levels</article-title>. <source>Acs Chem Neurosci</source> <volume>4</volume>, <fpage>930</fpage>–<lpage>939</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moradi-Marjaneh</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Paseban</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Marjaneh</surname>, <given-names>M. M.</given-names></string-name></person-group> <article-title>Hsp70 inhibitors: Implications for the treatment of colorectal cancer</article-title>. <source>IUBMB Life</source> <volume>71</volume>, <fpage>1834</fpage>–<lpage>1845</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abisambra</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau</article-title>. <source>Biol Psychiat</source> <volume>74</volume>, <fpage>367</fpage>–<lpage>374</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biamonte</surname>, <given-names>M. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Heat Shock Protein 90: Inhibitors in Clinical Trials</article-title>. <source>J Med Chem</source>. <volume>53</volume>, <fpage>3</fpage>–<lpage>17</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kundel</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsp70 Inhibits the Nucleation and Elongation of Tau and Sequesters Tau Aggregates with High Affinity</article-title>. <source>ACS Chem Biol</source>. <volume>13</volume>, <fpage>636</fpage>–<lpage>646</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patterson</surname>, <given-names>K. R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal Transport</article-title>. <source>Biochemistry</source> <volume>50</volume>, <fpage>10300</fpage>–<lpage>10310</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fontaine</surname>, <given-names>S. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins</article-title>. <source>EMBO J</source>. <volume>35</volume>, <fpage>1537</fpage>–<lpage>1549</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abisambra</surname>, <given-names>J. F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>DnaJA1 Antagonizes Constitutive Hsp70-Mediated Stabilization of Tau</article-title>. <source>J Mol Biol</source>. <volume>421</volume>, <fpage>653</fpage>–<lpage>661</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarkar</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kuret</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Lee</surname>, <given-names>G</given-names></string-name></person-group>. <article-title>Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone</article-title>. <source>J Neurosci Res</source> <volume>86</volume>, <fpage>2763</fpage>–<lpage>2773</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Joseph</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Anglada-Huguet</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Paesler</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mandelkow</surname>, <given-names>E.</given-names></string-name> &amp; <string-name><surname>Mandelkow</surname>, <given-names>E.-M</given-names></string-name></person-group>. <article-title>Anti-aggregant tau mutant promotes neurogenesis</article-title>. <source>Mol Neurodegener</source> <volume>12</volume>, <fpage>88</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pir</surname>, <given-names>G. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment</article-title>. <source>Mol Neurobiol</source> <volume>56</volume>, <fpage>3751</fpage>–<lpage>3767</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sydow</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant</article-title>. <source>J Neurosci</source> <volume>31</volume>, <fpage>2511</fpage>– <lpage>2525</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mocanu</surname>, <given-names>M.-M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The Potential for -Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy</article-title>. <source>J Neurosci</source> <volume>28</volume>, <fpage>737</fpage>–<lpage>748</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bergen</surname>, <given-names>M. von</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure</article-title>. <source>J Biol Chem</source> <volume>276</volume>, <fpage>48165</fpage>–<lpage>48174</lpage> (<year>2001</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morito</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Human MAPT knockin mouse models of frontotemporal dementia for the neurodegenerative research community. <italic>Cell Rep</italic></article-title>. <source>Methods</source> <volume>5</volume>, <fpage>101024</fpage> (<year>2025</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beckman</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A novel tau-based rhesus monkey model of Alzheimer’s pathogenesis</article-title>. <source>Alzheimer’s Dement</source>. <volume>17</volume>, <fpage>933</fpage>–<lpage>945</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scheres</surname>, <given-names>S. H.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Falcon</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Goedert</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>Cryo-EM structures of tau filaments</article-title>. <source>Curr Opin Struct Biol</source>. <volume>64</volume>, <fpage>17</fpage>–<lpage>25</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fitzpatrick</surname>, <given-names>A. W. P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cryo-EM structures of tau filaments from Alzheimer’s disease</article-title>. <source>Nature</source> <volume>547</volume>, <fpage>185</fpage>–<lpage>190</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tarutani</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cryo-EM structures of tau filaments from SH-SY5Y cells seeded with brain extracts from cases of Alzheimer’s disease and corticobasal degeneration</article-title>. <source>FEBS Open Bio</source> <volume>13</volume>, <fpage>1394</fpage>–<lpage>1404</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arakhamia</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains</article-title>. <source>Cell</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.01.027</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schweighauser</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cryo-EM structures of tau filaments from the brains of mice transgenic for human mutant P301S Tau</article-title>. <source>Acta Neuropathol Commun</source>. <volume>11</volume>, <fpage>160</fpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>, <given-names>W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cryo-EM structures reveal variant Tau amyloid fibrils between the rTg4510 mouse model and sporadic human tauopathies</article-title>. <source>Cell Discov</source>. <volume>10</volume>, <fpage>27</fpage> (<year>2024</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nixon</surname>, <given-names>R. A</given-names></string-name></person-group>. <article-title>Autophagy–lysosomal-associated neuronal death in neurodegenerative disease</article-title>. <source>Acta Neuropathol</source>. <volume>148</volume>, <fpage>42</fpage> (<year>2024</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ihara</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Morishima-Kawashima</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Nixon</surname>, <given-names>R.</given-names></string-name></person-group> <article-title>The Ubiquitin–Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease</article-title>. <source>Cold Spring Harb Perspect Med</source>. <volume>2</volume>, <fpage>a006361</fpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keller</surname>, <given-names>J. N.</given-names></string-name>, <string-name><surname>Hanni</surname>, <given-names>K. B.</given-names></string-name> &amp; <string-name><surname>Markesbery</surname>, <given-names>W. R</given-names></string-name></person-group>. <article-title>Impaired Proteasome Function in Alzheimer’s Disease</article-title>. <source>J Neurochem</source>. <volume>75</volume>, <fpage>436</fpage>–<lpage>439</lpage> (<year>2000</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bobkova</surname>, <given-names>N. V.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Therapeutic Effect of Exogenous Hsp70 in Mouse Models of Alzheimer’s Disease</article-title>. <source>J Alzheimer’s Dis</source>. <volume>38</volume>, <fpage>425</fpage>–<lpage>435</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nachman</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species</article-title>. <source>J Biol Chem</source> <volume>295</volume>, <fpage>9676</fpage>–<lpage>9690</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fontaine</surname>, <given-names>S. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics</article-title>. <source>Hum Mol Genet</source> <volume>24</volume>, <fpage>3971</fpage>–<lpage>3981</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name> &amp; <string-name><surname>Tohda</surname>, <given-names>C</given-names></string-name></person-group>. <article-title>Heat Shock Cognate 70 Inhibitor, VER-155008, Reduces Memory Deficits and Axonal Degeneration in a Mouse Model of Alzheimer’s Disease</article-title>. <source>Front Pharmacol</source>. <volume>9</volume>, <fpage>48</fpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jinwal</surname>, <given-names>U. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability</article-title>. <source>J Neurosci</source> <volume>29</volume>, <fpage>12079</fpage>–<lpage>12088</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Tau protein aggregates inhibit the protein-folding and vesicular trafficking arms of the cellular proteostasis network</article-title>. <source>J Biol Chem</source> <volume>294</volume>, <fpage>7917</fpage>–<lpage>7930</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dou</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Chaperones increase association of tau protein with microtubules</article-title>. <source>Proc National Acad Sci</source> <volume>100</volume>, <fpage>721</fpage>–<lpage>726</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vries</surname>, <given-names>L. E. de</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Gene-expression profiling of individuals resilient to Alzheimer’s disease reveals higher expression of genes related to metallothionein and mitochondrial processes and no changes in the unfolded protein response</article-title>. <source>Acta Neuropathol Commun</source>. <volume>12</volume>, <fpage>68</fpage> (<year>2024</year>).</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hondius</surname>, <given-names>D. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The proteome of granulovacuolar degeneration and neurofibrillary tangles in Alzheimer’s disease</article-title>. <source>Acta Neuropathol</source>. <volume>141</volume>, <fpage>341</fpage>–<lpage>358</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salminen</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ojala</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kaarniranta</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hiltunen</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Soininen</surname>, <given-names>H</given-names></string-name></person-group>. <article-title>Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease</article-title>. <source>Prog Neurobiol</source> <volume>93</volume>, <fpage>99</fpage>–<lpage>110</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moll</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsp multichaperone complex buffers pathologically modified Tau</article-title>. <source>Nat Commun</source> <volume>13</volume>, <fpage>3668</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karagöz</surname>, <given-names>G. E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action</article-title>. <source>Cell</source> <volume>156</volume>, <fpage>963</fpage>–<lpage>974</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cook</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation</article-title>. <source>Hum Mol Genet</source> <volume>21</volume>, <fpage>2936</fpage>–<lpage>45</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dickey</surname>, <given-names>C. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Akt and CHIP coregulate tau degradation through coordinated interactions</article-title>. <source>P Natl Acad Sci Usa</source> <volume>105</volume>, <fpage>3622</fpage>–<lpage>7</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weickert</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wawrzyniuk</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>John</surname>, <given-names>L. H.</given-names></string-name>, <string-name><surname>Rüdiger</surname>, <given-names>S. G. D.</given-names></string-name> &amp; <string-name><surname>Drescher</surname>, <given-names>M</given-names></string-name></person-group>. <article-title>The mechanism of Hsp90-induced oligomerizaton of Tau</article-title>. <source>Sci Adv</source> <volume>6</volume>, <fpage>eaax6999</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyata</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Cysteine Reactivity Distinguishes Redox Sensing by the Heat-Inducible and Constitutive Forms of Heat Shock Protein 70</article-title>. <source>Chem Biol</source>. <volume>19</volume>, <fpage>1391</fpage>–<lpage>1399</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shelton</surname>, <given-names>L. B.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsp90 activator Aha1 drives production of pathological tau aggregates</article-title>. <source>Proc National Acad Sci</source> <volume>114</volume>, <fpage>9707</fpage>–<lpage>9712</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jinwal</surname>, <given-names>U. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The Hsp90 Cochaperone, FKBP51, Increases Tau Stability and Polymerizes Microtubules</article-title>. <source>J Neurosci</source>. <volume>30</volume>, <fpage>591</fpage>–<lpage>599</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blair</surname>, <given-names>L. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Accelerated neurodegeneration through chaperone-mediated oligomerization of tau</article-title>. <source>J Clin Investig</source>. <volume>123</volume>, <fpage>4158</fpage>–<lpage>4169</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Webster</surname>, <given-names>J. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hsp22 with an N-Terminal Domain Truncation Mediates a Reduction in Tau Protein Levels</article-title>. <source>Int J Mol Sci</source>. <volume>21</volume>, <fpage>5442</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ospina</surname>, <given-names>S. R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Small Heat Shock Protein 22 Improves Cognition and Learning in the Tauopathic Brain</article-title>. <source>Int J Mol Sci</source> <volume>23</volume>, <fpage>851</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abisambra</surname>, <given-names>J. F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Phosphorylation Dynamics Regulate Hsp27-Mediated Rescue of Neuronal Plasticity Deficits in Tau Transgenic Mice</article-title>. <source>J Neurosci</source>. <volume>30</volume>, <fpage>15374</fpage>–<lpage>15382</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barghorn</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Biernat</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Mandelkow</surname>, <given-names>E.</given-names></string-name></person-group> <article-title>Amyloid Proteins, Methods and Protocols</article-title>. <source>Methods Mol Biol (Clifton, NJ)</source> <volume>299</volume>, <fpage>35</fpage>–<lpage>51</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farizatto</surname>, <given-names>K. L. G.</given-names></string-name>, <string-name><surname>Almeida</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>R. T.</given-names></string-name> &amp; <string-name><surname>Bahr</surname>, <given-names>B. A</given-names></string-name></person-group>. <article-title>Early Synaptic Alterations and Selective Adhesion Signaling in Hippocampal Dendritic Zones Following Organophosphate Exposure</article-title>. <source>Sci Rep</source>. <volume>9</volume>, <fpage>6532</fpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Almeida</surname>, <given-names>M. F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Distinct and dementia-related synaptopathy in the hippocampus after military blast exposures</article-title>. <source>Brain Pathol</source>. <volume>31</volume>, <fpage>e12936</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McKenna</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Organotypic whole hemisphere brain slice models to study the effects of donor age and oxygen-glucose-deprivation on the extracellular properties of cortical and striatal tissue</article-title>. <source>J Biol Eng</source>. <volume>16</volume>, <fpage>14</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bahr</surname>, <given-names>B. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein</article-title>. <source>J Comp Neurol</source>. <volume>397</volume>, <fpage>139</fpage>–<lpage>147</lpage> (<year>1998</year>).</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caba</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Excitotoxic stimulation activates distinct pathogenic and protective expression signatures in the hippocampus</article-title>. <source>J Cell Mol Med</source>. <volume>25</volume>, <fpage>9011</fpage>–<lpage>9027</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farizatto</surname>, <given-names>K. L. G.</given-names></string-name>, <string-name><surname>Ikonne</surname>, <given-names>U. S.</given-names></string-name>, <string-name><surname>Almeida</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Ferrari</surname>, <given-names>M. F. R.</given-names></string-name> &amp; <string-name><surname>Bahr</surname>, <given-names>B. A</given-names></string-name></person-group>. <article-title>Aâ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways</article-title>. <source>PLoS ONE</source> <volume>12</volume>, <fpage>e0182895</fpage> (<year>2017</year>).</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109145.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Keqiang</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution>
</institution-wrap>
<city>Shenzhen</city>
<country>China</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study presents <bold>compelling</bold> new data that combine two FTD-tau mutations, P301L/S320F (PL-SF), that reliably induce spontaneous full-length tau aggregation across multiple cellular systems. The findings are <bold>important</bold> for the field of neurodegenerative disease. The strength of evidence is <bold>solid</bold>; however, several conclusions would benefit from more validation.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109145.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This study presents compelling new data that combine two FTD-tau mutations P301L/S320F (PL-SF), that reliably induce spontaneous full-length tau aggregation across multiple cellular systems. However, several conclusions would benefit from more validation. Key findings rely on quantification of overexposed immunoblot, and in some experiments, the tau bands shift in molecular weight that are not explained (and in some instances vary between experiments). The effect seems to be driven by the S320F mutation, with the P301L mutation enhancing the effect observed with S320F alone. Although the observation that Hsp70, but not the related Hsc70, enhances aggregation is intriguing, the mechanistic basis for these differences remains unclear despite both Hsp70 and Hsc70 binding to tau. Additional experiments clarifying which PL-SF tau species Hsp70 engages, how this interaction alters tau conformational landscapes, and whether other chaperones or cofactors contribute to this effect would help solidify the conclusions and build a mechanistic picture. Overexpression of Hsp70 in the context of PL tau did not increase tau aggregation, which raises questions about whether the observed effects are specific to the SF mutation. Hsp70 functions in the context of a larger network of chaperones and has been proposed to cooperate with other proteins/machinery to disassemble tau amyloids, perhaps to produce more seeds. This would be consistent with the presented observations. For example, co-IP experiments using Hsp70 as bait combined with proteomics could really help build a more complete picture of what tau species Hsp70 binds and what other factors cooperate to yield the observed increases in aggregation. As it stands, the Hsp70 component of the paper is not fully developed, and additional experiments to address these questions would strengthen this manuscript beyond simply presenting a new tool to study spontaneous tau aggregation.</p>
<p>Strengths:</p>
<p>(1) The PL-SF FL tau mutant aggregates spontaneously in different cellular systems and shows hallmarks of tau pathology linked to disease.</p>
<p>(2) PL-SF 4delta mutant reverses the spontaneous aggregation phenotype, consistent with these residues being critical for tau aggregation.</p>
<p>(3) PL-SF 4delta also loses the ability to recruit Hsp70/Hsc70, consistent with these residues also being critical for chaperone recruitment.</p>
<p>(4) The PL-SF tau mutant establishes a new system to study spontaneous tau assembly and to begin to compare it to seeded tau aggregation processes.</p>
<p>Weaknesses:</p>
<p>(1) Mechanistic insight into how Hsp70 but not Hsc70 increase PL-SF FL tau aggregation/pathology is missing. This is despite both chaperones binding to PL-SF FL tau. What species of tau does Hsp70 bind, and what cofactors are important in this process?</p>
<p>(2) The study relies heavily on densitometry of bands to draw conclusions; in several instances, the blots are overexposed to accurately quantify the signal.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109145.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This study developed a novel tauopathy model combining two mutations, P301L and S320F, termed the PL-SF model. This model shows rapid tau protein aggregation.</p>
<p>Strengths:</p>
<p>The authors demonstrated pathogenicity through solid in vivo and in vitro experiments. Simultaneously, they used this model to investigate the role of the heat shock protein Hsp70 in tau protein aggregation, finding that Hsp70 promotes rather than inhibits tau pathology, which differs from previous findings.</p>
<p>Weaknesses:</p>
<p>(1) Although the PL-SF model can accelerate tau aggregation, it is crucial to determine whether this aligns with the temporal progression and spatial distribution of tau pathology in the brains of patients with tauopathies.</p>
<p>(2) The authors did not elucidate the specific molecular mechanism by which Hsp70 promotes tau aggregation.</p>
<p>(3) Some figures in this study show large error bars in the quantitative data (some statistical analysis figures, MEA recordings, etc.), indicating significant inter-sample variability. It is recommended to label individual data points in all quantitative figures and clearly indicate them in figure legends.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109145.1.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bryan</surname>
<given-names>Miles R</given-names>
<suffix>III</suffix></name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7105-0628</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Almeida</surname>
<given-names>Michael F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pellegrino</surname>
<given-names>Kyle</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Opland</surname>
<given-names>Carli K</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paulakonis</surname>
<given-names>J Ethan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGillion-Moore</surname>
<given-names>Jake</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trzeciakiewicz</surname>
<given-names>Hanna</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>King</surname>
<given-names>Diamond</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Xu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tseng</surname>
<given-names>Jui-Heng</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schisler</surname>
<given-names>Jonathan C</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7382-2783</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Nicholas G</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bahr</surname>
<given-names>Ben A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cohen</surname>
<given-names>Todd J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1</bold></p>
<p>(1) Mechanistic insight into how Hsp70 but not Hsc70 increase PL-SF FL tau aggregation/pathology is missing. This is despite both chaperones binding to PL-SF FL tau. What species of tau does Hsp70 bind, and what cofactors are important in this process?</p>
</disp-quote>
<p>We agree that explaining why Hsp70, but not Hsc70, promotes tau aggregation would strengthen the study. Although both chaperones bind tau, they diverge slightly in 1) protein sequence, 2) biochemical activity, and 3) co-chaperone engagement.</p>
<p>Sequence: Hsp70 has an extra cysteine residue (Cys306) that is highly reactive to oxidation and a glycine residue that is critical for cysteine oxidation (Gly557). Both residues are specific to Hsp70 (not present in Hsc70) and may alter Hsp70 conformation or client handling (Hong et al., 2022).</p>
<p>Biochemical activity: Prior studies indicate that Hsp70’s ATPase domain (NBD) is critical for tau interactions (Jinwal et al., 2009; Fontaine et al., 2015; Young et al., 2016) and can be disrupted with point mutations including K71E and E175S for ATPase and A406G/V438G for substrate binding (Fontaine et al., 2015).</p>
<p>Co-chaperone engagement: Hsp70 recruits the co-chaperone and E3 ubiquitin ligase CHIP/Stub1 more strongly than Hsc70, suggesting co-chaperone engagement could lead to differences in tau processing (Jinwal et al., 2013).</p>
<p>To directly test how the two closely related chaperones could differentially impact tau, we plan to perform the following experiments:</p>
<p>(a) We will mutate residues responsible for cysteine reactivity in Hsp70 including the cysteine itself (Cys306) and the critical glycine that facilitates cysteine reactivity (Gly557). These residues will be deleted from Hsp70 or alternatively inserted into Hsc70 to determine whether cysteine reactivity is the reason for Hsp70’s ability to drive tau aggregation.</p>
<p>(b) We will generate Hsp70 mutants lacking ATPase- or substrate-binding mutants to determine which Hsp70 domains are responsible for driving tau aggregation.</p>
<p>(c) We will perform seeding assays in stable tau-expressing cell lines to determine whether Hsp70/Hsc70 overexpression or depletion alters seeded tau aggregation.</p>
<p>(d) We will perform confocal microscopy to determine the extent of co-localization of Hsp70 or Hsc70 with phospho-tau, oligomeric tau, or Thioflavin-S (ThioS) to identify which tau species are engaged by Hsp70/Hsc70.</p>
<p>(e) We will perform immunoprecipitation pull-downs followed by mass spectrometry to globally identify any relevant Hsp70/Hsc70 interacting factors that might account for the differences in tau aggregation.</p>
<disp-quote content-type="editor-comment">
<p>(2) The study relies heavily on densitometry of bands to draw conclusions; in several instances, the blots are overexposed to accurately quantify the signal.</p>
</disp-quote>
<p>All immunoblots were acquired as 16-bit TIFFs with exposure settings chosen to prevent pixel saturation, and quantification was performed on raw, unsaturated images. Brightness and contrast adjustments were applied only for visualization and did not alter pixel values used for analysis. All quantified bands fell within the linear range of the detector, with one exception in Figure 7B, which we removed from quantification. We will add both low- and high-exposure versions of immunoblots to the revised figures to demonstrate signal linearity and dynamic range.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2</bold></p>
<p>(1) Although the PL-SF model can accelerate tau aggregation, it is crucial to determine whether this aligns with the temporal progression and spatial distribution of tau pathology in the brains of patients with tauopathies.</p>
</disp-quote>
<p>No single tauopathy model fully recapitulates the temporal and spatial progression of human tauopathies. The PL-SF system is not intended to model the disease course. Rather, it is an excellent model for mechanistic studies of mature tau aggregation, which is otherwise challenging to study. We note that prior studies showed that PL-SF tau expression in transgenic mice (Xia et al., 2022 and Smith et al., 2025) and rhesus monkeys (Beckman et al., 2021) led to prion-like tau seeding and aggregation in hippocampal and cortical regions. Indeed, the spatial and temporal tau aggregation patterns aligned with features of human tauopathies. So far, these findings all support PL-SF as a valid accelerated model of tauopathy than can be used to interrogate pathogenic mechanisms that impact tau processing, degradation, and/or aggregation.</p>
<disp-quote content-type="editor-comment">
<p>(2) The authors did not elucidate the specific molecular mechanism by which Hsp70 promotes tau aggregation.</p>
</disp-quote>
<p>We agree that a deeper understanding of the molecular mechanism is needed. The revision experiments outlined above (Reviewer #1, point #1) will define how Hsp70 promotes tau aggregation by testing sequence contributions, dissecting ATPase and substrate-binding domain requirements, and mapping Hsp70/Hsc70 interactors to directly address this mechanistic question.</p>
<disp-quote content-type="editor-comment">
<p>(3) Some figures in this study show large error bars in the quantitative data (some statistical analysis figures, MEA recordings, etc.), indicating significant inter-sample variability. It is recommended to label individual data points in all quantitative figures and clearly indicate them in figure legends.</p>
</disp-quote>
<p>We acknowledge the inter-sample variability in some of the quantitative datasets. This level of variability can occur in primary neuronal cultures (e.g., MEA recordings) that are sensitive to growth and surface adhesion conditions, leading to many technical considerations. To improve transparency and interpretation, we will revise all quantitative figures to display individual data points overlaid on summary statistics and will update figure legends to clearly indicate sample sizes and statistical tests used.</p>
<p>References</p>
<p>Hong Z, Gong W, Yang J, Li S, Liu Z, Perrett S, Zhang H. Exploration of the cysteine reactivity of human inducible Hsp70 and cognate Hsc70. J Biol Chem. 2023 Jan;299(1):102723. doi: 10.1016/j.jbc.2022.102723. Epub 2022 Nov 19. PMID: 36410435; PMCID: PMC9800336.</p>
<p>Jinwal UK, Miyata Y, Koren J 3rd, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci. 2009 Sep 30;29(39):12079-88. doi: 10.1523/JNEUROSCI.3345-09.2009. PMID: 19793966; PMCID: PMC2775811.</p>
<p>Fontaine SN, Rauch JN, Nordhues BA, Assimon VA, Stothert AR, Jinwal UK, Sabbagh JJ, Chang L, Stevens SM Jr, Zuiderweg ER, Gestwicki JE, Dickey CA. Isoform-selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement. J Biol Chem. 2015 May 22;290(21):13115-27. doi: 10.1074/jbc.M115.637595. Epub 2015 Apr 11. PMID: 25864199; PMCID: PMC4505567</p>
<p>Young ZT, Rauch JN, Assimon VA, Jinwal UK, Ahn M, Li X, Dunyak BM, Ahmad A, Carlson G, Srinivasan SR, Zuiderweg ERP, Dickey CA, Gestwicki JE. Stabilizing the Hsp70‑Tau Complex Promotes Turnover in Models of Tauopathy. Cell Chem Biol. 2016 Aug 4;23(8):992–1001. doi:10.1016/j.chembiol.2016.04.014.</p>
<p>Jinwal UK, Akoury E, Abisambra JF, O'Leary JC 3rd, Thompson AD, Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P, Zhang B, Borysov S, Uversky VN, Biernat J, Mandelkow E, Gestwicki JE, Zweckstetter M, Dickey CA. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J. 2013 Apr;27(4):1450-9. doi: 10.1096/fj.12-220889. Epub 2012 Dec 27. PMID: 23271055; PMCID: PMC3606536.</p>
<p>Xia, Y., Prokop, S., Bell, B.M. et al. Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Commun Biol 5, 446 (2022). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s42003-022-03373-1">https://doi.org/10.1038/s42003-022-03373-1</ext-link></p>
<p>Smith ED, Paterno G, Bell BM, Gorion KM, Prokop S, Giasson BI. Tau from SPAM Transgenic Mice Exhibit Potent Strain-Specific Prion-Like Seeding Properties Characteristic of Human Neurodegenerative Diseases. Neuromolecular Med. 2025 May 30;27(1):44. doi: 10.1007/s12017-025-08850-4. PMID: 40447946; PMCID: PMC12125038.</p>
<p>Beckman D, Chakrabarty P, Ott S, Dao A, Zhou E, Janssen WG, Donis-Cox K, Muller S, Kordower JH, Morrison JH. A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement. 2021 Jun;17(6):933-945. doi: 10.1002/alz.12318. Epub 2021 Mar 18. PMID: 33734581; PMCID: PMC8252011.</p>
</body>
</sub-article>
</article>